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ABSTRACT 
Molecular mechanisms of therapeutic resistance in cancer 
Development of therapeutic resistance limits the efficacy of current cancer 
treatment. Understanding the molecular basis for therapeutic resistance 
should facilitate the identification of actionable targets and development of 
new combination therapies for cancer patients. Yet the understanding of 
therapeutic resistance still remains incomplete. In this thesis, clinically 
relevant mouse models coupled with systematic genomic and imaging 
technologies are used to identify mechanisms driving resistance, which also 
formulate novel therapeutic paradigms for patients with drug-resistant tumors.  
In the first study, a genetically engineered mouse model of ovarian 
endometrioid adenocarcinoma (OEA) was utilized in combination with 
molecular imaging to understand mechanisms of chemoresistance in OEA. It 
was demonstrated that AKT signaling pathway was activated upon 
chemotherapy (cisplatin) administration, which protected cells from apoptosis 
and thereby leading to the development of resistance. In support of this 
observation, inhibition of AKT activity improved the efficacy of chemotherapy 
by enhanced induction of apoptosis. 
A second study was undertaken to develop a new understanding of the 
mechanistic basis for therapeutic resistance in glioblastoma using a patient 
derived xenograft model. An integrated transcriptome analysis revealed that 
chemoradioresistance was associated with an increased expression of genes 
involved in the mesenchymal and stem cell phenotype as well as a decreased 
expression of genes involved in cell death. TGF-β signaling was identified to 
be central to each of the mesenchymal/stem phenotype and therefore a 
critical
x	  	  
player in modulating therapeutic resistance. In support, treatment with a TGF-
β inhibitor partially restored the sensitivity to therapy in TMZ/IR resistant 
tumors.  
Overall, this thesis demonstrated the importance of the AKT and TGF-β 
signaling pathways in therapeutic resistance in a subset of ovarian cancer and 
glioblastoma patients, which provides clinical guidance for applying new 
combination therapies. It also demonstrates the concept that the combination 
of clinically relevant mouse models, molecular imaging and systematic 
genomic analysis can be used to derive novel insights into the dynamic 
signaling processes involved with gain of resistance. Future studies are 
needed to investigate if targeting these resistance mechanisms delays or 
prevents the development of resistance in treatment-naïve patients.  
 
 
 
CHAPTER I 
Introduction 
1.1 Therapeutic resistance in cancer  
1.1.1 Overview  
Cancer is the second leading cause of death in the United States. It is 
estimated that 1,665,540 new cancer cases will be diagnosed and 585,720 
patients will succumb to cancer in 2014 [1]. Besides surgery, chemotherapy 
and radiotherapy are the most common treatment options across different 
types of cancer [2]. They can be used singularly or in combination with other 
treatments such as hormone therapy. The benefits of chemotherapy and 
radiotherapy include: 1) killing cancer cells at the primary sites or 
metastasizing sites (e.g. lymphoma& breast cancer) [3, 4]; 2) preparing 
patients for surgery (e.g. esophageal cancer) [5]; 3) shrinking tumor sizes to 
relive patients from pain caused by cancer (e.g. bone metastasis) [6].  
While chemotherapy and/or radiotherapy remain as the major standard of care 
for cancer patients, the response to treatment varies substantially in different 
types of cancer, or even among patients with the same type of cancer. For 
example, chemotherapy is extremely successful in childhood acute 
lymphocytic leukemia (ALL) treatment [2], where over 95% of the patients 
attain remission and 91.7% of them survive over 5 years [7]. On the contrary, 
despite intensive combinatorial treatment of chemotherapy and radiotherapy, 
most glioblastoma patients suffer from tumor recurrence, where the median 
time to tumor progression is only about 6.9 months and the 5-year-survival rate 
is less than 10% [8]. In the case of triple negative breast cancer (negative for 
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estrogen receptors, progesterone receptors, and HER2), the pathologic 
complete response rates to neoadjuvant chemotherapy vary from 50% to 0% 
in basal-like 1 subtype and basal-like 2 subtype, respectively [9, 10]. The 
variations in treatment response suggest that intrinsic or acquired therapeutic 
resistance exists in a subset of cancer patients, which leads to treatment 
failures, disease progression, and eventually mortality. This pervasive barrier 
confounds the ultimate goal of curing or managing cancer in long term.  
The increasing knowledge of key driver genes in cancer has accelerated the 
development of novel targeted therapeutic agents over the past few decades. 
Many targeted therapies, including small molecule inhibitors and monoclonal 
antibodies, have been developed to target essential pathways in 
tumorigenesis and maintenance. This new category of therapy has 
demonstrated superior efficacy in eliminating cancer cells while sparing normal 
cells, thus resulting in less toxicity. A successful representative of targeted 
therapies is the anti-HER2 antibody (Trastuzumab®). Human epidermal 
growth factor receptor 2 (HER2) is a crucial oncogenic pathway in breast 
cancer. HER2 is overexpressed in 15-20% invasive breast cancer, and is 
associated with worse outcomes in patients. Laboratory experiments proved 
that aberrant HER2 signaling pathway is oncogenic and necessary for cancer 
cell survival, which formulated the strategy of anti-HER2 therapy. 
Trastuzumab® is a humanized monoclonal antibody, which can bind to HER2 
receptor and block HER2 signaling pathway [11]. Trastuzumab® in 
combination with chemotherapy has been shown to reduce the rate of tumor 
recurrence by half as well as decrease the mortality rate by a third among 
patients with HER2 positive breast cancer [12]. Additionally, Trastuzumab® 
does not show significant effect in HER2 negative patients, demonstrating the 
specificity of this therapy. 
This particularly triumphal case demonstrates the power of targeted therapy. 
Similarly, identifying key regulatory pathways in therapeutic resistance will 
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likely inform rationally-designed targeted therapies that overcome this problem 
in cancer patients. Yet the knowledge of therapeutic resistance still remains 
highly incomplete. The primary objective of this thesis is to elucidate the 
mechanisms of therapeutic resistance in ovarian cancer and glioblastoma, 
where therapeutic resistance contributes significantly to poor prognosis. 
Clinically relevant mouse models coupled with systematic genomic and 
imaging technologies will be used to identify key regulatory pathways in 
therapeutic resistance and plausible therapeutic avenue to intercept them. 
This knowledge can be leveraged to facilitate the development of salvaging 
therapeutic modules for future cancer patients. 
1.1.2 Chemoresistance in ovarian cancer  
Ovarian cancer is a leading cause of cancer death among American women 
[1]. Currently, surgery and chemotherapy are the standard of care for ovarian 
cancer patients. Despite an initial response to chemotherapy, patients tend to 
develop chemoresistance over time, which leads to poor prognosis [13]. 
Understanding the molecular basis of chemoresistance will aid in identification 
of new targets for ovarian cancer treatment, which will eventually improve 
patient outcomes. 
Platinum-based agents form the first-line chemotherapy for ovarian cancer 
patients. The molecular actions of these agents involve hydrolysis, drug 
transportation, formation of intra-/inter-strand crosslinks of DNA, and activation 
of apoptosis cascade if DNA damage is left unrepaired [14]. Alterations in any 
of these steps could lead to chemoresistance (Figure 1.1). Moreover, 
remodeling of the tumor microenvironment and tumor heterogeneity can 
further decrease chemosensitivity in cancer cells. In fact, numerous studies 
have explored each possibility and demonstrated their association with 
chemoresistance in ovarian cancer (reviewed in [15-17]). The following section 
will highlight some recent studies on chemoresistance in ovarian cancer with a 
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focus on novel regulatory mechanisms and clinical trials. 
DNA damage repair proficiency is a determinant for sensitivity to 
platinum-based agents [16] (Figure 1.2). Poly (ADP-ribose) polymerase 
(PARP) is a key player in repairing DNA single strand break (SSB). Inhibiting 
PARP may result in accumulation of SSB, and DSB subsequently. Phase-II 
clinical trials showed that a PARP inhibitor improved the outcomes of recurrent 
ovarian cancer patients as a single agent, including those who are resistant to 
platinum therapy [18, 19].  
Ovarian cancer stem cells were first documented in 2005. Since then, many 
studies have provided evidence of the existence and importance of this unique 
population in ovarian cancer [20-23]. Yet, the hunt for effective targets against 
ovarian cancer stem cells is still ongoing [24]. A recent study showed that the 
Notch signaling pathway is critical for regulation of cancer stem cells and 
resistance to platinum-based therapy in ovarian cancer. Combination of a 
Notch pathway inhibitor and cisplatin showed superior efficacy in inducing 
DNA damage, arresting cell cycle, enhancing apoptosis, reducing tumor 
burden, and finally prolonging survival in tumor bearing mice [25]. As Notch 
inhibitors are currently being evaluated in early clinical trials [26], this study 
may provide a rationale for testing the combination of Notch inhibitors and 
chemotherapy in chemoresistant ovarian cancer patients. 
Ovarian cancer microenvironment contributes to tumor growth, angiogenesis, 
dissemination, and chemoresistance (reviewed in [27]). One of the critical 
factors in ovarian cancer microenvironment is vascular endothelial growth 
factor (VEGF), which is a key regulator of angiogenesis and is associated with 
poor prognosis, and chemoresistance [28-30]. Bevacizumab, a monoclonal 
antibody against VEGF, has been tested in platinum-resistant recurrent 
ovarian cancer as an adjuvant therapy with chemotherapy in a phase III clinical 
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trial. The combination therapy prolonged tumor progression free time even 
though it has not shown significant benefits in overall survival [31].  
Previous research on chemoresistance in ovarian cancer has generated 
insights pertaining to DNA damage response, cancer stem cells, and tumor 
microenvironment. At the same time, limited clinical improvement indicates 
that this early work is still incomplete. One major drawback is that early 
resistance research often did not fully account for the spectrum of 
heterogeneity in ovarian cancer. Clinical and molecular findings suggest that 
ovarian cancer represents a group of heterogeneous neoplasms [32]. 
Currently there are no differences in treatment strategies among various types 
of ovarian cancer, however it is becoming evident that the inherent variances 
of ovarian cancer influence treatment efficacy and development of therapeutic 
resistance [33].  
Epithelial tumors account for approximately 90% of primary malignant ovarian 
cancer. Historically, epithelial ovarian cancer is classified into four major 
subtypes based on cell type, which include serous, endometrioid, clear cell, 
and mucinous subtypes [34]. Next generation sequencing revealed that both 
high-grade serous ovarian carcinoma (HGS-OvCa) and endometriod 
carcinoma can be further divided into various groups according to gene 
expression profiles [35, 36]. Yet the genetic drivers and corresponding 
biological features have not been well characterized in these subgroups. 
Previous molecular data suggests that the four major subtypes have distinct 
genetic alterations. For example, K-RAS gene mutations are found in about 
85% mucinous ovarian adenocarcinomas, but are much less frequently 
observed in other subtypes of ovarian carcinoma [37-39]. The canonical Wnt 
signaling pathway is shown to be deregulated in 16%–38% of human ovarian 
endometrioid adenocarcinomas (OEAs) while inactivating mutations of the 
tumor suppressor gene PTEN have been reported in 14%–21% of OEAs, but 
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are rare in the other types of ovarian carcinomas. More interestingly, Cho et al. 
showed that the defects in Wnt and PTEN signaling often occur concomitantly 
in a subset of OEA patients. By inactivating Apc and Pten in ovarian surface 
epithelium in a murine model, Cho et al. successfully recapitulated the 
histological features and gene expression profiles of human OEAs [40]. This 
mouse model of OEA provides a preclinical platform to study the biology of 
OEA as well as evaluate efficacies of new therapeutic paradigms [41]. 
Meanwhile, Chemoresistance mechanisms has not been investigated in OEA 
specifically. This model provides a platform to understand chemoresistance 
mechanisms in OEA and developing new therapeutic modules specifically for 
OEA patients. 
1.1.3 Chemoradioresistance in glioblastoma 
Glioblastoma (GBM) is the most aggressive and lethal brain tumor in adults. 
The median survival time of GBM patients is only about 15 months in the 
presence of surgery, chemotherapy and radiotherapy treatment. The majority 
patients suffer from tumor recurrence, which is the primary cause of death [8]. 
Yet, no effective therapies have been discovered for patients with recurrent 
tumors so far. 
Temozolomide (TMZ) is a widely used chemotherapy for glioblastoma 
treatment. It primarily mediates methylation of DNA at O6-guanine, which 
causes mismatch during DNA replication, resulting in DNA double strand break 
and subsequent apoptosis [42]. The O6-methyguanine-DNA methyltransferase 
(MGMT) is a suicide enzyme that can remove methyl-groups at O6-guanine 
sites and thus counteracts the lethal effect of TMZ. Elevated MGMT 
expression has been demonstrated to mediate resistance to TMZ [43]. 
Meanwhile, as DNA methylation plays an important role in regulating MGMT 
expression, the methylation status of MGMT promoter has been established 
as a critical prognostic factor for glioblastoma patients [8, 44]. However, many 
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studies, including in vitro, in vivo, and clinical studies have shown that the 
methylation status of MGMT promoter or MGMT expression does not always 
correspond with TMZ sensitivity, suggesting that MGMT might not be the only 
mechanism of therapeutic resistance in GBM [45-48].  
Numerous efforts have been invested to determine key regulators of 
therapeutic resistance in GBM. Yet heterogeneity, one hallmark of GBM, might 
have been underappreciated in previous studies. First, different populations of 
cancer cells exist in the same tumor [49-51], which might be responsible for 
partial or no response for single targeted agent treatment. Brain tumor stem 
cells are among the firstly identified cancer stem cells in solid tumors [52, 53].  
A recent study demonstrated that TMZ eliminated proliferating tumor cells but 
a quiescent population remained after treatment, which led to tumor 
recurrence. It shows that the therapeutic resistant clones exist before 
treatment, which can survive treatment and eventually regenerate tumor mass 
[54]. Further studies are needed to characterize this specific population and 
identify potential therapeutic targets. Secondly, genomic profiling has 
demonstrated that subtypes with distinguished genomic alterations exist in 
GBM, which would result in differences in treatment response. For example, 
patients with the mesenchymal subtype have worse outcomes compared to 
patients in other groups, suggesting that patients with the mesenchymal 
subtype are likely to be chemoradioresistant [55]. Yet, few studies have 
investigated therapeutic resistance in a subtype specific manner. 
The goal of the second part of this thesis is to depict a comprehensive picture 
of the molecular events leading to therapeutic resistance in a mouse model 
representing the heterogeneous disease. This knowledge will further guide 
research to pinpoint the master regulatory pathways and the subsequent 
development of targeted therapies for individual GBM patients.  
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1.2 Experimental approaches to study therapeutic resistance 
1.2.1 Studies of therapeutic resistance in mouse models 
As discussed earlier, one type of cancer can be further grouped into multiple 
genetically and morphologically distinctive groups, which has been proven in 
ovarian cancer as well as glioblastoma [56]. Moreover, patient outcomes and 
treatment response are associated with cancer subtypes, suggesting that the 
genetic signatures in each subtype influence the response to treatment. 
Therefore, individual genetic variances should be taken into account to fully 
understand mechanisms of therapeutic resistance. 
In order to address this challenge, a clinically relevant model system is 
required to recapitulate the heterogeneity of cancer. Mice are excellent models 
in cancer research for multiple reasons [57]. Over 95% of the mouse genome 
is similar to human genome and mice have similar metabolism system to 
human, which makes the research highly translatable. Mice provide tumor 
microenvironment that cannot be recapitulated in vitro, such as angiogenesis 
and immune response. Finally, mice have several traits that make them 
efficient tools for experimental studies, such as a short reproduction cycle, 
accelerated life span and small body sizes. 
Studies described in this thesis primarily utilized two types of cancer mouse 
models: genetically engineered mouse models and patient derived xenograft 
models. The advantages of each model, especially those related to therapeutic 
resistance research, are described below. 
Genetically engineered mouse models (GEMMs) 
GEMMs refer to mice with induced mutations, including transgenes, localized 
knockouts or knockins, or retroviral-, proviral- or chemical-induced mutations. 
GEMMs allow scientists to study the functions of specific genes as well as 
evaluate targeted therapeutic agents and treatment schedules. Various 
8
 
 
GEMMs with alterations in oncogenes or tumor suppressors have been 
generated, which faithfully recapitulate human cancer genetically and 
pathologically [58]. With advanced technology, such as CRISPR/Cas-mediated 
genome engineering, it is becoming less time-consuming and technically 
challenging to generate GEMMs with multiple genetic manipulations, which 
overall makes GEMMs more appealing for cancer research [59].  
GEMMs have multiple advantages compared to other mouse model systems. 
Firstly, most implanted cells/tumor specimens in xenograft models are from 
tumor masses at a detectable level, which usually happens much later after 
tumor initiation. GEMMs mimic the evolution of tumors from initiation to 
advanced stages, which provide the opportunity to study drug response at 
different stages of cancer progression. Secondly, GEMMs have uniform 
genetic background, which enable scientists to study one or more specific 
pathways simultaneously and thus eliminate interference from other potential 
genetic alterations. Inducible manipulation of oncogenes and tumor 
suppressor genes also allows scientists to differentiate molecular functions in 
tumor initiation and maintenance in cancer [60]. Lastly, GEMMs have fully 
functional immune systems and therefore can mirror tumor microenvironment, 
which plays a critical role in therapeutic response.  
Patient derived xenograft (PDX) model 
PDX models are renewable tumor models generated from tumor specimen of 
cancer patients. Tumor specimen (usually from surgery or biopsy) can be 
engrafted and propagated in immunodeficient mice directly. It can also be 
cultured briefly in vitro and then implanted into immunodeficient mice (Figure 
1.3) [61]. PDX models have been established for a variety of cancers, 
including pancreatic cancer [62], prostate cancer [63], ovarian cancer [64], and 
glioblastoma [65, 66]. 
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In comparison to traditional cell line derived xenograft models, PDX models 
retain the genomic alterations of primary tumors faithfully, which can be utilized 
to establish banks of PDX mice with different genetic background within the 
same type of cancer.  This system closely resembles the heterogeneity in 
cancer patients and allows scientists to study evolution of therapeutic 
resistance in individual patient. Moreover, new therapies can be evaluated in 
PDX mice to determine the most effective treatment options. This personalized 
pre-clinical trial will ideally speed up the process of clinical trials [67].  
Overall, GEMMs and PDX models represent state-of-the-art mouse models in 
cancer research, and provide clinically relevant platforms to investigate 
mechanisms of therapeutic resistance. 
1.2.2 Genomic and molecular studies of therapeutic resistance  
There are two overarching themes in therapeutic resistance research: 1) 
candidate driven research, where one gene or pathway is proposed to regulate 
therapeutic resistance and the hypothesis is tested experimentally; 2) 
unbiased studies, where large-scale genomic, transcriptomics, proteomic, or 
kinomic information is collected and analyzed to identify new mechanisms of 
therapeutic resistance [68]. 
This thesis explores both research themes. The PI3K/AKT signaling pathway 
is a critical oncogenic pathway in various types of cancer. It also has been 
shown to mediate chemoresistance in ovarian cancer cells by promoting cell 
survival, or escaping apoptosis [14]. However, the role of PI3K/AKT in 
chemoresistance has not been studied in OEA. By using molecular imaging 
tools, the role of AKT activity was evaluated in a clinically relevant mouse 
model of OEA in the first part of this thesis. In the second part of the thesis, an 
unbiased transcriptomic analysis was used to identify novel regulatory 
mechanisms of chemoradioresistance in glioblastoma. It has been 
demonstrated that cancer cells continuously divide, grow, invade, metastasize, 
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and avoid cell death through coordinated actions of oncogenes and tumor 
suppressor genes [69]. It is conceivable that tumor cells might survive 
treatment via multiple sophisticated therapeutic resistance pathways. This 
systematic analysis will shed lights to our understanding of key signaling 
networks and nodules for therapeutic resistance. Meanwhile, the role of key 
signaling pathways will be further pursued to validate their involvement in 
therapeutic resistance. 
In order to pursue candidate-driven research and systematic genomic 
research, two major experimental tools, including molecular imaging and RNA 
sequencing, were used in this thesis research.  
Molecular imaging 
Molecular imaging provides a platform to monitor treatment response 
accurately and noninvasively in live animals. It exploits specific molecular 
probes as well as intrinsic tissue characteristics as a source of imaging 
contrast, which can be used to characterize and quantify biological processes 
[70]. Molecular imaging modalities include optical imaging (bioluminescence 
imaging (BLI) and fluorescence imaging), magnetic resonance imaging (MRI), 
ultrasound imaging, positron emission tomography (PET), single-photon 
emission computerized tomography (SPECT), and computed tomography (CT) 
[71]. It possesses several advantages over conventional biochemical assays, 
especially for research in animal models. Molecular imaging can be performed 
repetitively, non-invasively, and in a relatively short time in the same living 
animal. Therefore, it can reduce the number of animals required for research, 
which reduces cost while retaining the statistical power for longitudinal studies. 
Furthermore, molecular imaging can provide detailed spatial and temporal 
information of biological events in living animals, which sometimes is 
overlooked in studies with end-point assays. Lastly, some imaging techniques 
are clinically transferable, which can facilitate discovery and validation of new 
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imaging surrogates for diagnosis or treatment response. For example, 
apparent diffusion co-efficiency (ADC), a parameter that measures water 
diffusion rates via diffusion-weighted MRI, has been used as a surrogate for 
treatment response in both pre-clinical animal models and clinical settings [72, 
73]. 
The two major imaging modules used in this thesis are BLI and MRI. BLI is 
based on the luciferin-luciferase enzymatic reaction, where visible light 
(bioluminescence) is generated as a by-product. The signal-to-noise ratio of 
BLI is excellent, thus generating high imaging sensitivity both in vitro and in 
vivo. As a part of the system, the luciferase gene is usually induced into cells 
or animals by transient transfection, virus-mediated transduction or genetic 
manipulation (e.g. homologous recombination). Luciferin can be delivered 
directly into cell culture or via injection in animals.  
The luciferin-luciferase system has been utilized to reveal cell mobility, gene 
expression patterns and biological activities in live cells or animals. For 
example, since the luciferase gene can be propagated during cell proliferation, 
the intensity and locations of bioluminescence signals correlate with the 
number of cells and their spatial distributions, which can be utilized to quantify 
tumor burden and metastasis. In a recent study, a transgenic mouse model of 
lung cancer was used to evaluate the role of IKK2 and NF-κB in lung cancer 
development. The mouse model contains alleles of mutated KRAS oncogene 
and luciferase gene, which is activated in a tissue specific manner by 
cre-mediated recombination. The orthotropic tumor burden was measured by 
BLI repeatedly upon IKK2 inhibitor treatment, which generated a longitudinal 
treatment response profile [74]. Another study investigated the role of CXCR7 
in regulating CXCR4+ cells metastasis by BLI. Tumor cells were labeled with 
luciferase gene and then implanted orthotopically. The bioluminescence 
intensity at various organ locations were monitored and used as an indication 
of metastasis capability [75]. 
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Besides the direct fusion of luciferase, split luciferase complementation has 
been used to monitor various biological activities. A luciferase gene is split into 
two complement components and the physical proximity between the two parts 
determines reconstitution of luciferase activity. This versatile technique is used 
to measure apoptosis, kinase activities, and protein-protein interactions. For 
example, an apoptosis reporter was developed with split luciferase 
components linked by a DEVD sequence, which can be recognized by 
activated caspase-3. Upon activation of apoptosis, the DEVD sequence is 
cleaved, thus allowing reconstitution of the luciferase activity [76]. Since 
apoptosis is a key parameter to measure treatment efficacy, this reporter has 
been adapted in high-throughput pro-apoptotic compound screening in cell 
culture as well as optimization of therapeutic treatment in live animals [77-79]. 
To monitor AKT kinase activity, the split subunits of luciferase are linked by an 
AKT substrate peptide and a phospho-specific binding peptide, where the two 
parts of luciferase only reconstitute enzyme activity in the absence of AKT 
activation [80]. Similar kinase reporters also include a smad2/TGF-β reporter, 
a cMET reporter, an EGFR reporter and an ATM reporter [81-84]. Lastly, split 
luciferase complementation allows detection of protein-protein interactions. 
For example, a beetle red luciferase complementation reporter was recently 
developed by Luker et al.. This reporter measures CXCL12-dependent 
activation of CXCR4 both in cell culture and in live animals. More specifically, 
split luciferase fragments were fused to CXCL12 and β-arrestin 2 separately. 
Luciferase activity was determined by the interaction between CXCL12 and 
β-arrestin 2, which corresponded to CXCL12 signaling activity [85]. 
MRI is another major imaging modality used in this thesis. Unlike BLI, MRI 
does not require introduction of exogenous genes to create detectable contrast. 
It is based on the signals emitted by excited hydrogen atoms that are present 
in any tissue containing water molecules. The differences in water content 
among different tissues generate the contrast signals, which can be collected 
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and reconstructed into 3D images. To improve image quality, contrast agents, 
such as gadolinium, may be used. MRI serves a wide range of purposes in 
pre-clinical research. The most basic application of MRI is to generate 3D 
image atlases, which can be used to detect tumor locations, monitor tumor 
volumes, and characterize histology features. MRI can also track cells 
noninvasively with iron oxide- and 19F-based probes, which are used to 
monitor therapeutic delivery and immune response [86]. Some other advanced 
MRI techniques are developed to broaden MRI applications and improve 
cancer management clinically. For example, diffusion weighted MRI, which 
was mentioned earlier, has been applied in multiple areas, including tumor 
characterization, tumor grading, prognosis prediction, and treatment 
monitoring [87].  
RNA sequencing 
To identify the molecular basis underlying therapeutic resistance, a 
comprehensive approach is required to identify the genome-wide alterations 
responsible for therapeutic resistance. One such approach is RNA sequencing, 
which can reveal genome-wide gene expression patterns. RNA sequencing is 
derived from next generation sequencing (NGS); NGS technology deciphers 
DNA sequence by identifying fluorescence signals emitted from nucleotides 
that is incorporated into the DNA strand during double strand synthesis. This 
process is extended to billions of short DNA strands in parallel. In the case of 
RNA sequencing, RNA is first extracted from tissues or cells and then 
converted to cDNA by reverse transcription. Once cDNA is synthesized, it can 
be further fragmented into ideal sizes for NGS. Millions of short reads are 
obtained and assembled into transcriptome either by aligning reads to a 
reference genome or by de novo assembling without the genomic references 
[88]. High-throughput sequencing technology has drastically revolutionized the 
way scientists acquire genetic information [89]. 
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Compared to microarrays, a commonly used hybridization-based approach for 
transcriptome quantifications, RNA sequencing possesses several advantages. 
First, no previous knowledge of candidates’ genome is required. Microarrays 
rely on existing knowledge of gene sequences for probe design while RNA 
sequencing detects RNA from de novo sequencing, which allows detection of 
new RNA species or genomic events. For example, RNA sequencing identified 
novel recurrent transcript fusions in glioma, which revealed a new aspect of 
genomic alterations upon treatment [90]. Secondly, microarrays have limited 
sensitivity and require large amount of RNA materials whereas RNA 
sequencing has a much larger dynamic range and only needs a tiny amount of 
starting materials [91]. Currently, RNA sequencing can be adapted to single 
cell resolution, which has been utilized to configure the evolution map during 
tumorigenesis as well as development of therapeutic resistance [49, 92].  
RNA sequencing has revealed multiple new insights into cancer biology since 
its debut. It allows detection of transcript fusions, splicing events as well as 
new RNA species, including long non-coding RNA (lncRNA) [90, 93, 94]. It can 
also map differentially expressed genes in two or more sample sets, identify 
prognostic or predictive gene signatures associated with outcomes, and 
pinpoint new regulatory pathways. For example, RNA sequencing of 
neuroendocrine prostate cancer (NEPC) and prostate adenocarcinoma (PCA) 
samples found that AURKA and MYCN genes are overexpressed in about 40% 
NEPC. Moreover, NEPC showed high sensitivity to Aurora kinase inhibitor, 
indicating that AURKA might be a potential target in at least a subset of NEPC 
[95].  
Overall, both candidate-driven and discovery-oriented research are capable of 
informing new knowledge of therapeutic resistance. This thesis combines both 
research types via molecular imaging and RNA sequencing, which provides 
new insights into therapeutic resistance in ovarian cancer and glioblastoma. 
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1.3 Conclusion 
Therapeutic resistance leads to treatment failures and mortality in patients.  
Yet the resistance mechanisms still remains incomplete. This thesis aims to 
decipher mechanisms of therapeutic resistance by using molecular imaging 
and high throughput sequencing technologies in clinically relevant mouse 
models. Actionable targets will be identified and evaluated in conjunction with 
the standard of care, which will provide a rationale for further investigation of 
such treatment regimens in clinical trials. 
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Figure 1.1 Mechanisms of action of chemotherapy and radiotherapy. Both 
chemotherapy and radiotherapy cause direct or indirect DNA damage, which 
triggers cell cycle arrest. DNA repair machinery attempts to repair the damage 
and allows cells to proceed into mitosis. If it fails to do so, cells will eventually 
undergo cell death, which could be apoptosis, necrosis, or autophagy.  Cell 
survival signaling pathways influence the efficacy of chemotherapy and 
radiotherapy by regulating DNA repair pathways, cell cycle and cell death. 
Intracellular concentration of chemotherapeutic agents is regulated by 
membrane drug transporters. 
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Figure 1.2 Overview of DNA damage and DNA repair mechanisms. 
Chemotherapy and radiotherapy induce various types of DNA damage, 
including base alkylation, base mismatches, base insertions, base deletions, 
bulky adducts, double strand breaks and single strand breaks. The major DNA 
repair pathways are direct reversal, base excision repair, nucleotide excision 
repair, mismatch repair, non-homologous end joining and homologous 
recombination.  
18
 
 
 
Figure 1.3 Schematic of patient derived xenograft models. Tumor 
specimens are collected from surgery or biopsy procedures in cancer patients. 
Tumor cells can be either engrafted and propagated in immunocompromised 
mice directly or cultured briefly in vitro and then implanted into mice. Ideally, 
genomic analysis and cryopreservation will be conducted before engraftment. 
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CHAPTER II 
Molecular Imaging  
Reveals a Role for AKT in Resistance to Cisplatin  
for Ovarian Endometrioid Adenocarcinoma 
Summary 
Ovarian cancer is the fifth leading cause of cancer deaths among American 
women. Platinum-based chemotherapy, such as cisplatin, represents the 
standard of care for ovarian cancer. However, toxicity and acquired resistance 
to cisplatin have proven challenging in the treatment of ovarian cancer patients. 
Using a genetically engineered mouse (GEM) model of ovarian endometrioid 
adenocarcinoma (OEA) in combination with molecular imaging technologies, 
we studied the activation of the AKT serine/threonine kinase in response to 
long-term cisplatin therapy. Treatment of cells in culture and tumor-bearing 
animals with cisplatin resulted in activation of AKT, a key mediator of cell 
survival. Based on these results we investigated the therapeutic utility of AKT 
inhibition in combination with cisplatin, which resulted in enhanced and 
prolonged induction of apoptosis and in significantly improved tumor control 
compared to either agent alone. These results provide an impetus for clinical 
trials using combination therapy. To facilitate these trials, we also demonstrate 
the utility of diffusion-weighted MRI as an imaging biomarker for evaluation of 
therapeutic efficacy in OEA.
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2.1 Introduction 
Among American women, ovarian cancer remains the fifth leading cause of 
cancer related deaths with an estimated 22,280 new cases for the year 2012 
[1]. At diagnosis, nearly two thirds of women with ovarian cancer present with 
advanced stage disease, and their overall five-year survival is only 27% [2, 3]. 
The vast majority of ovarian cancers are epithelial (carcinomas) and can be 
classified into four major subtypes, including serous, endometrioid, clear cell, 
and mucinous carcinomas [4]. Recent efforts to better understand the genetic 
differences between these subtypes have shown that mutations predicted to 
dysregulate key signaling pathways characterize each subtype [5].  For 
example, mutations of genes in the Wnt/β-catenin and PI3K/Pten signaling 
pathways co-occur in a substantial fraction of ovarian endometrioid 
adenocaraciomas (OEAs) [6]. Although genetic differences in the subtypes of 
ovarian cancer have been recognized, surgical debulking followed by 
chemotherapy with taxanes and platinum-based drugs remains the first-line 
therapy for all subtypes [7]. Unfortunately, even though most patients initially 
respond to treatment, tumors eventually relapse due to acquired drug 
resistance [8, 9]. To overcome these hurdles, dose escalation studies have 
been explored but have been found intolerable due to toxicity and serious 
side-effects [10]. Therefore, a better understanding of the mechanisms leading 
to drug resistance is urgently needed for the development of novel treatment 
paradigms to improve length and quality of life for ovarian cancer patients.  
The cisplatin-resistant phenotype of cancer cells may be due to a number of 
mechanisms, including alterations that affect the intracellular uptake of 
cisplatin or altered sigaling pathways that ultimately impact the execution of 
the apoptotic program [10]. The PI3K/AKT signaling pathway is important for 
cell survival, and plays a critical role in a number of other tumor-associated 
cellular processes, including cell growth, and cell cycle progression [11]. 
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Moreover, a recent study in cultured cells suggested that chemoresistance is 
mediated by AKT activation through DNA dependent protein kinase (DNA-PK) 
[12]. However, limited work has been done to study the molecular basis of 
chemoresistance in a clinically relevant mouse model of ovarian cancer. We 
have previously described a genetically engineered mouse (GEM) model for 
OEA, which recapitulates the human disease more closely than traditionally 
utilized tumor xenograft models. In this model, simultaneous activation of 
canonical Wnt/β-catenin and PI3K/AKT signaling invariably leads to ovarian 
tumor development and is achieved by conditionally inactivating the Apc and 
Pten tumor suppressor genes in the ovarian surface epithelium of 
ApcloxP/loxP ;PtenloxP/loxP mice [6].  Tumors arise as early as three weeks post 
expression of Cre recombinase, and the utility of this model for testing novel 
therapies or treatment paradigms has been recently demonstrated [13].  
Molecular imaging provides a unique opportunity to evaluate drug target 
interactions, induction of cell death, and tumor regression in a non-invasive 
and dynamic manner [14, 15]. Using a bioluminescence reporter for AKT 
activity [16] and caspase-3 proteolysis [17], we provide evidence in the mouse 
model that the activation of the PI3K/AKT cell survival signaling pathway in 
response to cisplatin treatment contributes to resistance to cisplatin-induced 
apoptosis. Simultaneously, we here describe a new modification of our 
genetically engineered mouse model for OEA, wherein tumor specific 
caspase-3-dependent apoptosis can be imaged over time in response to 
therapeutic intervention. We provide validation studies for the use of 
diffusion-weighted MRI (DW-MRI) as an imaging surrogate for treatment 
efficacy and identified cisplatin in combination with perifosine as a therapeutic 
paradigm for future clinical trials. 
2.2 Materials and Methods 
Cell culture 
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Murine OEA-derived tumor cell lines were established by mechanically 
dispersing ovarian tumor tissues with sterile scalpels followed by digestion at 
37oC with 0.05% Trypsin-EDTA for 20 minutes.  Cells were cultured for five 
passages in DMEM containing 10% FBS/1% Penicillin/Streptomycin (P/S)/1% 
Insulin-Transferrin-Selenium (Invitrogen) in an incubator with 3% O2/5% CO2 
(Model NAPCO 8000WJ, Thermal Scientific, Asheville, NC).  During the first 
five passages of primary culture, all non-adherent cells were discarded, and 
only adherent cells were passaged.  Adherent mesenchymal cells were 
removed by differential trypsinzation to further enrich the epithelial cell 
population.  The Apc-/Pten- OEA-derived tumor cell line W2532T, denoted 
hereafter as W25, was maintained in DMEM medium (Gibco, Gaithersburg, 
MD) supplemented with 10% fetal bovine serum (Gibco).   W25 cells display 
epithelial (cobblestone) morphology by light microscopy, and express epithelial 
markers cytokeratin 8 and 19 by immunofluorescence[13].  Cre-mediated 
bi-allelic recombination of Apc and Pten in W25 cells was confirmed by 
PCR.   To generate stable cell lines with bioluminescence reporters, W25 cells 
were transfected with plasmids (pEF apoptosis or AKT reporter) [16, 17] by 
using FuGENE 6 transfection reagent (Roche Diagnostics, Indianapolis, IN) 
following the manufacturer’s instructions. Single clones stably expressing the 
reporters were maintained in DMEM medium with 10% FBS and 300µg/mL 
G418 (Invitrogen, CA). 
Mouse Strains 
ApcloxP/loxP ;PtenloxP/loxP mice have been previously described in detail [6]. The 
transgenic bioluminescence-apoptosis reporter (Apoptosis reportertg/+) mouse 
was generated by the transgenic core of the University of Michigan. In brief, 
the Elongation Factor-1(EF1) promoter, which is widely and constitutively 
expressed, drives the transcription of the tdTomato coding sequence (a 
derivative of red fluorescent protein). The presence of a transcription stop site 
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and poly-adenylation target site (pA) at the end of the tdTomato coding 
sequence results in termination of transcription such that only the tdTomato 
protein is expressed. In the presence of Cre recombinase, recombination of 
the loxP sequences results in deletion of the tdTomato coding sequence as 
well as the adjoining pA sequences. Cre recombination of the transgene 
results in transcription of the molecular imaging reporter as well as an internal 
ribosome entry site (IRES) and the renilla luciferase (rluc) coding sequence.  
A single mRNA from the transgene will express the reporter protein (apoptosis 
reporter) as well as the rluc protein.  
ApcloxP/loxP;PtenloxP/loxP;Apoptosis reportertg/+ mice were generated by 
crossbreeding ApcloxP/loxP;PtenloxP/loxP mice with Apoptosis reportertg/+ mice.  
All the animal experiments were done in accordance with protocols approved 
by University Committee on Use and Care of Animals of the University of 
Michigan (UCUCA protocol numbers 08669 and 09921). 
Genotyping 
Animals were genotyped using tail DNA. Genotyping primers used in this study 
are listed here: PtenloxP/loxP allele: forward primer 
5'-CTCCTCTACTCCATTCTTCCC-3' and reverse primer 
5'-ACTCCCACCAATGAACAAAC-3' [18]; ApcloxP/loxP allele: forward primer 
5'-GTTCTGTATCATGGAAAGATAGGTGGT-3' and Reverse primer 
5'-CACTCAAAACGCTTTTGAGGGTTGATTC-3' [19]; Apoptosis reportertg/+ 
allele: forward primer 5’-GAAGTATAGCAACAGAAGACGCCAAAAACATA-3’ 
and reverse primer 5’-CTAGAAATAGATCTCCCTCCTCCATCGACTTC-3’. 
Western blot analysis 
Cells were washed with phosphate-buffered saline (PBS) and lysed with 
NP-40 lysis buffer (1% NP40, 150 mM NaCl, and 25 mM Tris, pH 8.0) 
supplemented with protease inhibitors (Complete Protease Inhibitor Cocktail, 
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Roche) and phosphatase inhibitors (PhosSTOP, Roche). Tumor tissues were 
collected at indicated time points, snap-frozen in liquid nitrogen, and stored at 
-80oC. Tissues were then homogenized in NP-40 lysis buffer supplemented 
with protease inhibitors and phosphotase inhibitors. Concentration of protein 
was determined using Lowry assays (Bio-Rad, Hercules, CA). Equal amount 
of protein was loaded in each lane and resolved by 4-12% gradient Bis-Tris gel 
(Invitrogen, CA). Proteins were transferred to 0.2 µm nitrocellulose membrane 
(Invitrogen, CA). Membranes were incubated overnight at 4oC with primary 
antibodies after blocking, followed by incubation with appropriate 
HRP-conjugated secondary antibody at room temperature for one hour. 
ECL-Plus was used to detect the activity of peroxidase according to the 
manufacturer’s protocol (Amersham Pharmacia, Uppsala, Sweden). 
Antibodies raised against PARP, pAKT (Serine473 and Thr308), total AKT, 
pH2A.X(Ser139) and total H2A.X were purchased from Cell Signaling 
Technology (Beverly, MA). 
Immunohistochemistry 
After drug treatment, all mice were euthanized and tumor tissues were 
collected, fixed in 10% (v/v) buffered formalin, and embedded in paraffin. 
Immunohistochemical (IHC) staining for Ki67 was completed by the Tissue 
Core of the University of Michigan Comprehensive Cancer Center using 
standard techniques. Images from two representative 600X fields in the most 
cellular areas of tumors were acquired by Olympus BX-51 upright light 
microscope and an Olympus DP-70 high resolution digital camera (Olympus 
Corporation of the Americas, Center Valley, PA). Ki67 positive cells and 
negative cells were counted by ImageJ software (Wayne Rasband, National 
Institutes of Health, MD).  
Bioluminescence imaging of cell culture 
Cells were seeded at 5,000 cells/well in a 96-well dish. 24 hours post seeding, 
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cells were incubated with indicated drugs for 20 hours prior to adding luciferin 
at a final concentration of 100 µg/ml. Luminescence was recorded by a 
luminometer (EnVision Xcite Multilabel Reader, PerkinElmer, Waltham, MA). 
PI exclusion assay 
Cell viability was determined by propidium iodide (PI) exclusion assay. PI was 
purchased from Invitrogen (Eugene, OR).  Cells were seeded at 1 x 105 
cells/ml. 24 hours post seeding, cells were incubated with indicated drugs for 
48 hours prior to trypsinization and subsequently collection by centrifugation 
(400g for 3 minutes). PI staining solution was added at a final concentration of 
0.1ug/ml. Percentage of PI positive cells was determined and recorded by BD 
FACSCantoTM Flow cytometry (BD Biosciences, San Jose, CA). 
Allograft Implantation 
6-week-old athymic female mice (CD-1 nu/nu, Charles River Laboratory, 
Wilmington, MA) were inoculated subcutaneously (s.c.) with 1x107 W25 cells 
expressing the bioluminescence reporters (apoptosis or Akt) into the flank on 
each side. Injections were a total volume of 200 µl cell suspension in 50% 
DMEM mixed with 50% BD Matrigel Matrix (Becton, Dickinson and Company, 
NJ). Caliper measurements were performed weekly to determine tumor 
volumes using the formula V= (length/2)x(width2) until s.q. tumors reached an 
approximate volume of 200 mm3 at which time each animal was randomized 
into one of four treatment groups. 
Intra-bursal injection 
Replication-incompetent recombinant adenovirus expressing Cre recombinase 
(AdCre) under the control of the CMV promoter [20] was obtained from the 
University of Michigan’s Vector Core. 5 x 107 plaque-forming units (p.f.u.) of 
AdCre were injected in a total volume of 5 µl containing 0.1% Evans blue 
(Sigma-Aldrich Inc., St. Louis, MO) into the right ovarian bursal cavity of 8- to 
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10-week-old female ApcloxP/loxP;PtenloxP/loxP; Apoptosis reporter tg/+ mice. 
Intrabursal injection was performed as previously described [21, 22]. Each 
mouse’s left ovarian bursa was untreated, thereby serving as control.  
Drug administration 
Control and perifosine-treated animals received vehicle or 10 mg/kg perifosine 
by intraperitoneal injection (i.p.), respectively, five times a week for two weeks 
with two days off in between treatment weeks. Animals in the cisplatin group 
received 2.5 mg/kg or 5 mg/kg cisplatin by i.p. injection twice a week for two 
weeks. For combination groups, mice were treated with 2.5 mg/kg or 5 mg/kg 
cisplatin twice a week with co-administration of 10 mg/kg perifosine.  
In vivo Bioluminescence imaging 
In vivo bioluminescence imaging was carried out by injecting tumor-bearing 
nude and genetically engineered mice intraperitoneally with 150 or 300 mg/kg 
of 40 mg/mL D-luciferin (Biosynth, Naperville, IL)/PBS solution, respectively, 
using an IVIS imaging system (Xenogen, Alameda, CA).  Post injection mice 
were anesthetized with a 1–2% isoflurane/air mixture and serial images were 
acquired over 20-30 minutes  to capture the peak photon emission for each 
animal. Regions of interest were drawn around the area of interest in each 
mouse and peak luminescence values of each series were used for analysis. 
MR-Imaging 
MR imaging on OEA mice was carried out on a 7T Agilent, Inc. (Palo Alto, 
CA) Direct Drive system with a quadrature mouse body volume coil (m2m 
Imaging Corp., Cleveland, OH). During all MRI procedures, animals were 
anesthetized with a 1–2% isoflurane/air mixture while maintaining body 
temperature using a heated air system (Air-Therm Heater, World Precision 
Instruments, Sarasota, FL). Anatomical MR images were acquired by a fast 
spin echo sequence with the following parameters: repetition time/echo time 
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(TR/TE) = 4000/15 ms, field of view (FOV)=40x30, matrix size=128x128, slice 
thickness=0.5 mm, echo train=8, echo spacing=15ms, and number of slices: 
25~30. OEA mice were screened for tumor burden once per week from the 
fourth week post intra-bursal surgery. Mice were randomized into vehicle, 
cisplatin, perifosine or cisplatin plus perifosine group when their orthotopic 
tumor sizes reached approximately 50 mm3. Mice were imaged by MRI twice 
weekly to follow tumor sizes during treatment. 
DW-MR images were obtained from a diffusion-weighted spin-echo sequence, 
with the following parameters: TR/TE = 2000/32 ms, FOV = 30×30, matrix size 
= 128×64, slice thickness = 1.0 mm, 10 slices, 2 averages, b-values (diffusion 
weighting) of 128 and 795 s/mm2. Respiratory gating was performed using a 
monitoring system (Small Animal Instruments, Inc., Stony Brook, NY) to 
eliminate motion artifacts from breathing. DW-MRI scans were performed 
before treatment and seven days post treatment initiation. 
Image Reconstruction and Analysis 
Volumes of interest (VOIs) were manually contoured around the enhancing rim 
of the tumors on the anatomical images for measurements of tumor volume. To 
determine the whole-tumor means of ADC (apparent diffusion coefficient), 
VOIs were manually contoured around the enhancing rim of the tumors on 
diffusion-weighted image slices at b=128 s/mm2. ADC maps were calculated 
from the two diffusion weightings (b-values) using the following equation: 
ADC= ln (
S1
S2
) (b2-b1)⁄  
where S1 and S2 are the signal intensities at b-values b1 and b2, respectively. 
Voxels that exhibited insufficient signal, defined as <10*noise, in the low 
b-value image (b = 128 s/mm2) were excluded from the analysis. Subsequently, 
mean ADC values were calculated over the entire tumor volume. All image 
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reconstruction and digital image analysis was accomplished using programs 
developed in Matlab (The Mathworks, Natick, MA, USA). 
2.3 Results 
2.3.1 Resistance to apoptosis in response to cisplatin is reversed by AKT 
inhibition 
To study the mechanistic basis of cisplatin chemoresistance, we established a 
primary ovarian tumor cell line (W25) derived from our previously described 
murine OEA model [13]. To enable imaging of caspase-3 activation, a 
surrogate for apoptosis, we generated a stable cell line (W25-Apop) 
expressing a previously described bioluminescent apoptosis reporter [17] as 
illustrated in Figure 2.1A. 
The induction of apoptosis was evaluated using cultured cells in response to 
cisplatin alone (20 µM) or in combination with perifosine (30 µM), a small 
molecule inhibitor of AKT activity [23]. As depicted in Figure 2.1B, combination 
therapy resulted in significantly elevated caspase-3 activation when compared 
to single agent as measured by an increase in bioluminescence signal. This 
finding was consistent with conventional western blot analysis for caspase-3 
activity as measured by cleavage of PARP, which was only observed in 
response to combination therapy (Figure 2.1C). Additionally, we evaluated 
overall cell viability using PI exclusion assays (Figure 2.1D), wherein the 
combination therapy showed higher percentage of PI positivity compared to 
either agent alone. 
To extend these studies in vivo, initial studies focused on following the 
treatment effects of subcutaneous W25-Apop tumors growing in athymic nude 
mice. Animals treated with vehicle, perifosine (10 mg/kg, 5 times a week), 
cisplatin (5 mg/kg, 2 times a week), or combination treatment of cisplatin (5 
mg/kg, 2 times a week) and perifosine (10 mg/kg, 5 times a week) were 
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studied using the bioluminescence molecular reporters. The greatest induction 
of apoptosis as measured by bioluminescence was observed in the cohort of 
animals treated with the combination of cisplatin and perifosine (Figure 2.2A 
and 2.2B). Treatment of tumor-bearing animals with perifosine resulted in 
enhanced bioluminescence signals (5 fold) on each day of treatment during 
the first week over the control group. Perifosine as a single agent failed to 
induce apoptosis during the second week (days 8-12). The combination of 
cisplatin and perifosine induced apoptosis to a similar extent as perifosine 
alone in the first week of treatment (5-6 fold) but a significant increase in 
apoptosis (10 fold) was observed in the second week of treatment (Figure 
2.2A). A significant degree of toxicity as measured by loss of weight was 
observed in mice treated with cisplatin at 5mg/kg, twice a week. To further 
evaluate the efficacy of cisplatin and perifosine, we used a lower dose of 
cisplatin (2.5mg/kg, twice a week). At these doses we observed a similar 
enhancement of bioluminescence in the combination group, compared to 
cisplatin alone after the first day of treatment (Figure 2.2C). Furthermore, by 
the end of two weeks of treatment both cisplatin and perifosine as single 
agents showed significantly increased tumor volumes over baseline 
measurements while the combination treatment prevented tumor growth 
during the treatment period (Figure 2.2D).  Cisplatin alone had some 
anti-tumor effect, as tumors were smaller in cisplatin-treated mice than in mice 
treated with vehicle alone over the 2 week treatment period. 
2.3.2 A role for AKT in resistance to cisplatin treatment. 
To investigate the regulation of AKT activity in live cells and animals, we used 
our previously described bioluminescence AKT reporter (BAR, Figure 2.3A). 
The reporter is designed such that increased bioluminescence activity is 
observed upon inhibition of the AKT-kinase [16]. Using BAR-expressing W25 
cells (W25-BAR) we evaluated AKT activity in response to cisplatin and/or 
perifosine. As expected, perifosine treatment resulted in a significant increase 
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of bioluminescence activity due to AKT inhibition. Unexpectedly, the 
combination of cisplatin and perifosine showed a six fold increase of 
bioluminescence, suggesting that cisplatin treatment elevated AKT kinase 
activity and that perifosine treatment resulted in a greater decrease in AKT 
activity (Figure 2.3B). This was confirmed by phospho-AKT western blot 
analysis which showed that both Ser473 and Thr308 phosphorylation was 
elevated upon cisplatin treatment in W25-BAR cells whereas perifosine 
treatment reversed AKT phosphorylation (Figure 2.3C). To investigate if this 
phenomenon was reproducible in tumors, AKT activity in response to therapies 
was evaluated in W25-BAR allografts. W25-BAR tumor-bearing animals were 
randomized into four groups consisting of control (vehicle), cisplatin (2.5 mg/kg, 
2 times a week), perifosine (10 mg/kg, 5 times a week) or combination therapy 
when tumors reached 200mm3 in volume. As shown in Figure 2.3D, treatment 
of s.q. tumor bearing mice with perifosine expectedly resulted in increased 
bioluminescence during treatment. In accordance with cell culture results, 
animals treated with the combination of cisplatin and perifosine showed a 
prolonged and enhanced increase in bioluminescence signal in the second 
week of treatment, indicative of enhanced AKT inhibition (and therefore 
activity). We hypothesized that repetitive cisplatin exposure during the first 
week of treatment elevated phospho-AKT levels in tumor allografts thereby 
allowed for increased bioluminescence signal to be detected due to 
simultaneous AKT inhibition. To test this hypothesis, tumor samples were 
collected following the first week (cycle) of therapy. Western blot analysis 
confirmed that cisplatin treatment resulted in an increase in AKT activation as 
measured by phospho-AKT. Combination treatment showed decreased levels 
of phospho-AKT compared to cisplatin alone indicating that perifosine 
treatment reversed the activation of AKT (Figure 2.3E). 
AKT phosphorylation is regulated by various factors, including DNA damage 
caused by radiation and chemotherapies [12, 24]. In order to evaluate the DNA 
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damage response pathway following cisplatin treatment, phosphorylation of 
histone H2A.X levels were evaluated. As shown in Figure 2.3F, 
phospho-H2A.X was induced in cisplatin and combination treatment groups, 
indicating that cisplatin treatment resulted in DNA damage inducing AKT 
activation. 
2.3.3 Imaging of apoptosis in a GEM model. 
The tumor microenvironment - including adjacent normal tissue, stromal cells, 
vasculature, lymph and immune cells - impacts the response of tumor cells to 
therapeutic intervention [25, 26]. For the purpose of imaging apoptosis 
non-invasively in an ovarian cancer animal model, we generated a new 
reporter mouse by pronuclear microinjection of a transgene containing the 
apoptosis reporter into fertilized eggs obtained from FVB/N females. The 
schematic diagram shown in Figure 2.4A depicts the transgene apoptosis 
reporter construct. Apoptosis reporter tg/+ transgenic animals were crossed with 
ApcloxP/loxP; PtenloxP/loxP mice to generate ApcloxP/loxP; PtenloxP/loxP; Apoptosis 
reporter tg/+ mice for use in subsequent experiments. 
In this new OEA model with the built-in apoptosis imaging reporter, 
Cre-expression resulted in the deletion of both copies of Apc and Pten and 
expression of the apoptosis reporter in transformed ovarian surface epithelial 
cells. Mice injected with AdCre are referred hereafter as Apc-/-; Pten-/-; 
Apopreporter+, indicating successful Cre-mediated recombination. 
Representative images of bioluminescence activity in Apc-/-; Pten-/-; 
Apopreporter+ mice with ovarian tumors before and following one day of 
treatment are shown in Figure 2.4B. Bioluminescence signals were only 
detected in the right abdomen, indicative of tissue-specific activation of the 
apoptosis reporter upon AdCre injection into the right ovary. Consistent with 
our previous data obtained in cell culture and allografts, bioluminescence 
activity increased following combination therapy indicating activation of 
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caspase-3 had occurred. Tumor progression in Apc-/-; Pten-/-; Apopreporter+ 
animals was followed over time using MRI beginning at four weeks post AdCre 
injection. Once tumor volumes reached approximately 50mm3, animals were 
randomized into four treatment groups: vehicle, perifosine, cisplatin and 
combination therapy. Following treatment initiation, bioluminescence imaging 
was performed 6 hours post treatment on days 1, 5, 8 and 12. Apoptosis 
reporter activation was normalized to tumor volume changes by performing 
MRI at the same time points in which bioluminescence imaging was performed. 
As demonstrated in Figure 2.4C, the combination treatment of perifosine and 
cisplatin resulted in the highest and most sustained induction of 
bioluminescence when compared to vehicle treated or single agent treated 
animals, indicating maximum apoptotic cell kill was achieved. Similar to the 
data obtained from the allograft study, we observed an increase in the level of 
apoptosis in perifosine treated animals 6 hours post treatment initiation. As 
mentioned above, the initial surge in cell death upon phospho-AKT inhibition 
might be due to the cells’ addiction to activated PI3K/AKT pathway. In fact, 
inhibition of the PI3K/AKT pathway in cancer cells has been shown to induce 
apoptosis [23]. Although no caspase-3 activation upon single agent cisplatin 
treatment was observed using bioluminescence imaging, tumor growth was 
inhibited as assessed by MRI (Figure 2.4E) indicative of caspase-3 
independent cytotoxicity due to the high dose of cisplatin which was also 
observed in our allograft study (Figure 2.2A). Quantitative analysis of the MRI 
data show tumor volumes were significantly reduced in the combinatorial 
treatment over all other treatment groups (Figure 2.4E), thus confirming our 
previous results using the OEA tumor allografts. Target inhibition by drug was 
confirmed by western blotting against phospho-AKT(Ser473) and total AKT of 
tumor tissues obtained from animals treated with perifosine. As depicted in 
Figure 2.4F, perifosine treatment resulted in a decrease in phospho-AKT levels 
at 3 hours post-treatment initiation. 
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DW-MRI can be used to measure changes in cellular density within tumor 
tissue and has been established as a clinically relevant surrogate imaging 
biomarker for treatment response assessment in cancer patients [27, 28]. We 
performed DW-MRI on tumor-bearing mice in order to evaluate the effects the 
treatment as well as the ability of DW-MRI to detect and differentiate the 
effectiveness of each treatment. As shown in Figure 2.5A and Figure 2.5B, we 
observed a decrease in ADC values in vehicle and perifosine-treated animals 
after two weeks of treatment suggesting that perifosine alone is not efficacious 
in inducing cell death. The observed decrease in ADC values in vehicle and 
perifosine groups suggested that cells were undergoing active proliferation 
resulting in increased tumor cellularity over this time period. This finding was 
further supported by immunohistochemical analysis of tumors obtained from 
these animals one week after treatment initiation. Ki67 staining, indicative of 
cell proliferation, increased in vehicle and perifosine-treated animals as shown 
in Figure 2.5C and Figure 2.5D. However, cisplatin and combination treated 
animals showed increased ADC values (Figure 2.5A and Figure 2.5B) and 
decreased Ki67 staining (Figure 2.5D), which suggested that increased cell 
death was the likely cause of the resultant tumor regression as demonstrated 
in Figure 2.4E. 
In summary, these studies revealed that combination treatment of cisplatin and 
perifosine was more efficacious than either drug alone in inducing apoptosis, 
and thereby tumor regression, by utilizing our new reporter mouse model of 
OEA in conjunction with non-invasive imaging modalities. 
2.4 Discussion 
Ovarian cancer patients treated with the chemotherapeutic agent, cisplatin, 
usually show an initial response yet ultimately succumb to their disease due to 
the development of resistance [10]. Regulation of cellular drug uptake, 
increased DNA damage repair, and inhibition of apoptosis have been proposed 
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to cause cisplatin resistance [29]. The development of strategies for 
chemosensitization and prevention of therapeutic resistance remains a major 
goal with important clinical implications. Although a large body of work has 
been conducted towards this aim, the model systems typically employ cultured 
cells and/or immunocompromised mice bearing subcutaneous xenografts. In 
addition, analyses of molecular events in these model systems involves 
resection of tumor cells for ex vivo assays and thus provide only a 
non-quantitative snapshot of a dynamically changing and highly interactive 
cascade of signaling events following therapeutic intervention. The present 
study utilizes recent advances in genetically engineered mouse ovarian cancer 
models as well as the development of molecular imaging biomarkers which 
enable quantitative, non-invasive and temporal imaging of dynamic molecular 
events in living animals. Combining our tumor model systems with anatomical 
and molecular imaging approaches provided an opportunity to gain novel 
insights into the roles of PI3K/AKT signaling and the apoptotic machinery in 
the development of therapeutic resistance to cisplatin. 
Our initial study utilized a mouse OEA cell line derived from an ovarian tumor 
which was engineered to express the apoptosis reporter. This line was 
subcutaneously implanted allowing for detection of caspase-3 activation in 
perifosine treated animals using bioluminescence imaging. While the imaging 
signal increased during the first week, a significant decline was observed 
during the second week of treatment. We reasoned that the cells’ dependency 
on the PI3K/AKT pathway leads to an initial induction of apoptosis upon 
inhibition of AKT activity by perifosine, which may later be compensated by 
activation of alternate survival signaling pathways. In support, we and others 
have previously reported that AKT inhibition results in activation of 
compensatory signaling through MEK/ERK or other signaling pathways [13, 
30]. This finding may provide additional rationale for the simultaneous 
targeting of PI3K/AKT and MEK/ERK signaling pathways, but remains to be 
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investigated for the treatment of OEA. Intriguingly, the caspase-3 reporter 
allowed us to determine that cell death and tumor regression induced by 
cisplatin in cell culture and in allografted or transgenic animals, respectively 
appeared to be largely caspase-3 independent. This is not surprising since 
cisplatin has been shown to exert its effects by inducing DNA damage, cell 
cycle arrest and ultimately necrotic cell death [31, 32] which serves to further 
validate the use of these molecular imaging reporters in the context of 
pre-clinical drug optimization studies. 
Initial response to platinum-based therapies in the treatment of patients 
afflicted with ovarian cancer is usually high, yet most patients relapse due to 
acquired resistance. Recent studies by Stronach et al. comparing 
cisplatin-resistant and cisplatin-sensitive cell lines revealed a significant 
increase in phosphorylated AKT upon cisplatin treatment. AKT inhibition 
sensitized resistant cells to cisplatin, whereas inhibition of AKT in cisplatin 
sensitive lines had little effect on caspase-3/7 induction [12]. With the ability to 
image and thus quantify AKT and caspase-3 activity in live tumor-bearing 
animals dynamically over time, our results support the concept that activation 
of AKT contributes to cisplatin resistance and likely results from prior exposure 
to the agent. 
Activation of AKT is regulated by various factors, including insulin and the DNA 
damage response. Several reports have thus far demonstrated that AKT’s 
complete activation depends on its phosphorylation at Ser473 and Thr308. 
Interestingly, Thr308 is phosphorylated by 3-phosphoinositide-dependent 
kinase 1 (PDK1) [33] whereas Ser473 is likely regulated by mammalian target 
of rapamycin complex 2 (mTORC2) [34], DNA-PK [35] and ATM [36]. Here we 
present data indicating that cisplatin alone or in combination with perifosine 
induced similar DNA damage, yet single agent treatment with cisplatin induced 
AKT activation and resistance to apoptosis. These findings suggest that AKT 
activation by cisplatin may be mediated by the DNA damage response. 
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Supporting these findings are the results of a recent study, which 
demonstrated DNA-PK dependent regulation of AKT phosphorylation upon 
cisplatin treatment [12]. However, since ATM is also activated following DNA 
double strand breaks and has been implicated in radiation-induced AKT 
activation [24], the possibility remains that ATM may also play a role in 
regulating AKT phosphorylation which should be the subject of further 
investigations. 
The PI3K/AKT pathway plays an important role in the cell survival pathway. 
The enhanced effect which we observed following cisplatin and perifosine 
treatments suggests that cisplatin activates the PI3K/AKT pathway thereby 
preventing apoptosis. Simultaneous inhibition of AKT activity by perifosine 
treatment can overcome this effect resulting in apoptosis. In fact, previous 
studies have shown that AKT through the modulation of p53 activity as well as 
activation of various apoptotic factors can lead to resistance to apoptosis 
[37-39].  
Genetically engineered OEA mouse models closely recapitulate the human 
disease, thereby providing an excellent opportunity to study this subtype of 
ovarian cancer and optimize therapeutic paradigms for future clinical 
investigation [13]. We have recently shown that the OEAs arising in our model 
system are inhibited by the mTOR inhibitor rapamycin, two mechanistically 
distinct AKT inhibitors (perifosine and API-2), as well as cisplatin plus 
paclitaxel [13], but combinations of conventional with targeted therapies have 
not been evaluated in our model system until now. Though we have not yet 
tested effects of cisplatin and perifosine in GEM models of serous carcinoma, 
we note that a substantial fraction of high grade serous carcinomas also have 
activated PI3K/AKT signaling, often on the basis of amplification PIK3CA, 
AKT1, or AKT2[5]. Hence our finding that cisplatin plus perifosine is more 
effective than either agent alone, may apply to other ovarian cancer subtypes 
besides the subset of endometrioid carcinomas with activated PI3K/AKT 
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signaling. We also note that other chemotherapeutic agents used to treat 
ovarian cancers, including paclitaxel, have also been shown to activate 
PI3K/AKT signaling [40]. In addition, inhibition of PI3K has been shown to 
increase efficacy of paclitaxel in ovarian cancer model systems [41]. Even 
more recently, perifosine plus docetaxel were used to treat patients with 
platinum and taxane resistant or refractory ovarian carcinomas in a Phase I 
clinical trial [42]. Interestingly, all four (of 21) patients who achieved partial 
remission or stable disease had either endometrioid or clear cell carcinomas, 
and two had mutations predicted to activate PI3K/AKT signaling. Clearly, more 
work is required to determine whether activation of AKT by cisplatin or 
paclitaxel is a drug-specific or more general effect, and to define the tumor 
subsets most likely to respond to therapeutic regimens including PI3K/AKT 
pathway inhibitors.   
Monitoring tumor progression and molecular events in intra-abdominal tumors 
usually involves sacrificing large number of animals for traditional biochemical 
assays. In order to enable the detection of molecular events within tumors 
longitudinally, we utilized our previously developed bioluminescence reporters 
along with anatomical- and DW-MR imaging. The use of the bioluminescence 
reporters provided for the ability to quantify the extent of apoptosis and AKT 
activation over time. We demonstrated in vivo that repeated cycles of cisplatin 
treatment resulted in AKT activation, thus revealing molecular mechanisms 
that contribute to the development of cisplatin resistance. The combination of 
cisplatin and perifosine was able to inhibit AKT activity and overcome 
resistance to cisplatin through apoptotic induction and therefore may present a 
more effective therapeutic paradigm for the treatment of ovarian patients. 
Although bioluminescence imaging represents a vital tool for imaging 
molecular events in animal models, it has its limitations in the clinical settings. 
In order to develop an imaging biomarker that can be clinically translated for 
use with ovarian cancer patients, we evaluated the application of DW-MRI as a 
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surrogate for detection of treatment associated loss of tumor cellularity. 
DW-MRI has shown promise as a surrogate biomarker of therapeutic response 
with correlations to survival outcomes in cancer patients [27, 43, 44]. In our 
study, DW-MRI revealed that both high doses of cisplatin and in combination 
with perifosine, significant loss of tumor cellularity occurs in contrast to 
treatment using perifosine alone which was found to have a minimal effect on 
reducing tumor cell density. 
In summary, animal models with defined mutations in key signaling pathways 
are powerful tools to provide a better understanding of therapeutic efficacy of 
single agents and to explore the efficacy of combination therapeutic strategies. 
Molecular imaging technologies such as bioluminescence imaging of mouse 
models as well as MRI in pre-clinical and clinical studies not only provide an 
accurate and non-invasive measure of tumor burden and efficacy, but can also 
enable validation of drug target interactions and acquired drug resistance. 
Results described here provide an impetus for initiation of clinical studies with 
integrated DW-MRI biomarker readouts to evaluate pharmacological inhibition 
of the PI3K/AKT survival signaling pathway when combined with cisplatin to 
prevent the development of therapeutic resistance and thus significantly 
impact overall survival in women with OEA. 
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Figure 2.1 Perifosine sensitizes ovarian tumor cells to cisplatin-induced 
apoptosis. (A) Schematic of bioluminescent apoptosis reporter molecule. 
Wildtype luciferase was separated into two peptides, N-terminal luciferase 
(N-luc) and C-terminal luciferase (C-luc). The two termini were separated by a 
linker region and the DEVD sequence, a recognition- and cleavage site of 
activated caspase-3. Two strong interacting peptides, namely peptide A and 
peptide B were fused to N-luc and C-luc, respectively. Upon cleavage at DEVD, 
peptide A and peptide B overcome the hindrance created by the linker region 
and reconstitute wildtype luciferase activity by bringing N-luc and C-luc in 
proximity. (B) Bioluminescence assay in W25-Apop cells post 20 hours 
treatment with PBS, cisplatin [20 µM], perifosine [30 µM] or both of perifosine 
and cisplatin. Fold induction of bioluminescence signals in each group was 
calculated at indicated time points by normalizing bioluminescence signals to 
the values of vehicle group. Three independent experiments were performed 
and data ± SEM is depicted. (C) Representative western blot for PARP in 
W25-Apop cells treated by cisplatin and/or perifosine for 20 hours. Cleaved 
PARP (89 kDa) was only observed in cells treated with combination of cisplatin 
and perifosine. (D) Percent cell death was assessed by PI exclusion assay of 
W25-Apop cells treated for 48 hours with PBS, cisplatin [20 µM], perifosine [30 
µM] or both (perifosine and cisplatin). Data was obtained from three 
independent experiments and represent mean ± SEM. 
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Figure 2.2 Induction of apoptosis in tumor allograft by combination 
treatment. (A) Bioluminescence imaging of W25-Apop allografts. When 
tumors reached ≥ 200 mm3, animals were randomized into four treatment 
groups: vehicle, perifosine (10 mg/kg 5 times a week), cisplatin (5 mg/kg 2 
times a week) and combination group which were treated with 5 mg/kg 
cisplatin 2 times a week and 10 mg/kg perifosine 5 times a week. Arrows 
indicate days of treatment for cisplatin and perifosine. Bioluminescence signals 
were normalized to tumor volumes and pre-treatment values at each time point. 
Mean fold induction is plotted ± SEM. (B) Representative BLI images pre- and 
post-treatment of each treatment group are shown. (C) Bioluminescence 
imaging of W25-Apop allografts at lower cisplatin doses (2.5mg/kg) at one time 
point (6 hours post treatment). Bioluminescence signals were normalized to 
pre-treatment values at each time point. Mean fold induction is plotted ± SEM. 
(D) Percent change of tumor volumes two weeks post treatment initiation. 
Tumor volumes were measured by caliper pre- and post- treatment. Data 
represent mean ± SEM.  
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Figure 2.3 Cisplatin induces increase in AKT phosphorylation. (A) 
Schematic of Bioluminescence AKT Reporter (BAR). (B) Bioluminescence 
assay in W25-BAR cells post 20 hours treatment with vehicle, cisplatin [40 µM], 
perifosine [30 µM] or both of perifosine and cisplatin. Fold induction of 
bioluminescence signals in each group was calculated at indicated time points 
by normalizing bioluminescence signals to the values of vehicle group. Three 
independent experiments were performed and mean ± SEM is depicted. (C) 
Representative western blot of W25 cell lysates from vehicle-, cisplatin [40µM]-, 
perifosine [30µM]- or both treated cells. Antibodies against pAKT Ser473, 
pAKT Thr308 and total AKT were used. (D) Bioluminescence imaging of 
W25-BAR reporter allografts. When tumors reached ≥ 200 mm3, animals were 
randomized into four treatment groups: vehicle, perifosine (10 mg/kg 5 times a 
Figure 2.3 
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week), cisplatin (2.5 mg/kg 2 times a week) and combination group which are 
treated with 2.5 mg/kg cisplatin 2 times a week and 10 mg/kg perifosine 5 
times a week. Arrows indicate days of treatment for cisplatin and perifosine. 
Bioluminescence signals were normalized to tumor volumes and pre-treatment 
values at indicated time points. Mean fold induction is plotted ± SEM. (E) 
Representative images of western blot analysis of tumor tissue derived from 
OEA transgenic at one week post cisplatin treatment. Antibodies against pAKT 
Ser473, pAKT Thr308 and total AKT were used. (F) Representative images of 
western blot analysis from W25 cells treated with vehicle, cisplatin [40 µM], 
perifosine [30 µM] or both. pH2A.X Ser139 and total H2A.X were detected by 
specific antibodies. 
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Figure 2.4 Inhibition of AKT activity potentiates the efficacy of cisplatin in 
a genetically engineered mouse model of OEA. (A) Schematic of the 
bioluminescence apoptosis reporter transgene. EF-1 alpha drives expression 
of floxed fluorescence protein tdTomato, which is removed upon tissue specific 
Cre recombination. Conditional Cre recombination leads to transcription of the 
bioluminescent apoptosis reporter and IRES dependent renilla luciferase 
expression. (B) Representative bioluminescence images from Apc-/-, Pten -/-, 
Apopreporter+ animals before treatment and one day after treatment. 
Bioluminescence signal is detected in the right but not left ovaries of animals. 
(C) When tumor size reached ≥ 50 mm3 animals were randomized into four 
Figure 2.4 
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treatment groups and BL- and MR- imaging was performed before treatment 
and on day1, day 5, day 8 and day 12 post treatment initiation. Fold induction 
was calculated by normalizing bioluminescence signals to tumor volumes 
acquired by MRI and pre-treatment values at each time point. Data represents 
mean ± SEM. (D) Representative MR images of animals in each group pre- 
and two weeks post treatment. (E) Percent change in tumor volume as 
measured by MR imaging. Data represents mean ± SEM. Statistical 
significance was assessed at a p<0.05 (*) using an unpaired Student’s t-test. 
(F) Representative images of western blotting analysis for total AKT and pAKT 
(Ser473) 3 hours post treatment with perifosine of tumors obtained from Apc-/-, 
Pten -/-, Apopreporter+ animals. 
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Figure 2.5 Diffusion-weighted MRI serves as an imaging surrogate for 
treatment response in OEA. (A) Representative ADC maps of tumor bearing 
Apc-/-, Pten -/-, Apopreporter+ animals treated with vehicle, cisplatin, perifosine 
or combined treatment before treatment and one week after treatment. (B) 
Percent change of ADC values and statistical analysis of each treatment group 
after one week of treatment. Mean is plotted± SEM. (C) Representative 
images of Ki67 staining of tumor tissues from each treatment group after one 
week of treatment: (a) vehicle, (b) cisplatin, (c) perifosine and (d) combination. 
(D) Percent change of Ki67 stained cells of each treatment group with 
statistical analysis. Mean is plotted ± SEM. 
  
Figure 2.5 
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CHAPTER III 
Coevolution of Mesenchymal and Stem Cell Signatures 
Promotes Therapeutic Resistance in Glioblastoma 
Summary 
Glioblastoma (GBM) represents the most aggressive malignant primary brain tumor. 
Radiation (IR) with concomitant and adjuvant temozolomide (TMZ) after surgical 
resection is the standard of care for newly diagnosed GBM patients. Despite an 
initial response, most patients succumb to the disease due to the development of 
resistance such that the median survival is only 15 months. In an effort to delineate 
the mechanistic basis for resistance to TMZ and IR, we utilized a patient derived 
intracranial xenograft mouse model coupled with MRI-guided stereotactic biopsy and 
RNA sequencing. Gene expression profiling of pre-treatment and recurrent tumor 
biopsy samples revealed a common signaling network underlying therapeutic 
resistance. The dominant feature of this network was an increased expression of 
genes involved in the mesenchymal and stem cell phenotype and a decreased 
expression of genes involved in cell death. TGF-β signaling was identified to be 
central to each of the mesenchymal/stem cell phenotype and therefore a key player 
in modulating therapeutic resistance. In support, treatment of tumor bearing animals 
with a TGF-β inhibitor partially restored the sensitivity to therapy in TZM/IR resistant 
tumors. This study provides a rationale for clinical trials wherein TGF-β inhibitors can 
be used in combination with chemoradiotherapy in GBM patients. 
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3.1 Introduction 
Glioblastoma (GBM) is the most aggressive and common malignant glioma [1]. The 
median survival of GBM patients is only around 15 months, and less than 10% of 
patients survive beyond 5 years [2]. Current treatment for GBM patients includes 
surgery followed by temozolomide (TMZ) and radiation (IR) [3]. Although the extent 
of surgical resection has a strong effect on overall survival and progression free 
survival [4-6], most GBM patients will go through subsequent radiation and 
chemotherapy treatment. Yet, a majority of patients experience tumor recurrence in 
the presence of continued therapy [2], indicating the development of resistance to 
TMZ and/or IR.  
Numerous efforts have been undertaken to delineate the mechanisms of TMZ/IR 
resistance. Some studies have focused on testing specific hypotheses, such as 
defects in DNA repair pathways. One prominent factor in TMZ resistance is O6-
methylguanine-DNA methyltransferase (MGMT). MGMT is a crucial member in 
repairing alkylating DNA damage and has often been identified as a predictor of 
treatment resistance in GBM [7].  However, evidence from in vivo, in vitro, and 
clinical studies has shown that MGMT expression does not always correspond with 
TMZ sensitivity, suggesting that MGMT is not the sole mechanism of treatment 
resistance [8-11]. Other studies have utilized genomic data and bioinformatics tools 
to identify genes associated with poor patient outcomes or treatment response [12-
14], which could be potential mediators of TMZ/IR resistance. While these studies 
identified various predictive or prognostic gene signatures, the role of each individual 
gene or group of genes is unclear. Consequently, the mechanisms of therapeutic 
resistance still remain elusive. There is an urgent need to combine systematic 
genomic profiling and functional analysis to understand the mechanisms of TMZ/IR 
resistance, which will facilitate identification of actionable therapeutic targets in GBM. 
In this study, we performed RNA sequencing in pre-treatment and recurrent tumor 
biopsy samples from a patient derived xenograft mouse model, where we identified a 
fine-tuned network underlying therapeutic resistance. In all recurrent cases, the 
expression of mesenchymal and stem cell genes was upregulated while the 
expression of cell death genes was downregulated. Inhibiting TGF-β signaling 
reduced the expression of both mesenchymal and stem cell genes and partially 
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restored TMZ/IR sensitivity. These findings establish TGF-β signaling as a promising 
therapeutic target against TMZ/IR resistance. 
3.2 Methods 
Patient derived primary neurosphere culture 
Low passage, patient derived primary GBM neurosphere cells have been previously 
described [15], and were maintained in neurosphere medium composed of 
DMEM/F12 medium (#11320-033, Life Technologies, Carlsbad, CA) plus N2 
supplement(#17502-048, Life Technologies, Carlsbad, CA), 0.5mg/ml BSA (#A4919, 
Sigma-Aldrich Co., St. Louis, MO), 25µg/ml Gentamicin (#15750-060, Life 
Technologies, Carlsbad, CA), 0.5% antibiotic/antimycotic (#15240-096, Life 
Technologies, Carlsbad, CA), 20ng/ml bFGF and 20 ng/ml EGF (#100-15 and #100-
18B, PeproTech, Rocky Hill NJ).  
Intracranial Implantation 
Cultured neurosphere cells were dissociated and suspended in DMEM/F12 medium, 
and implanted intracranially into five-week-old Athymic Nude Foxn1nu mice (Harlan 
Laboratories, Indianapolis, IN). Mice were anesthetized with a ketamine/xylazine 
(0.1/0.02mg/kg) mixture and the head surface was prepared with topical antiseptic 
solution (70% ethanol). A 1cm incision was made 2mm to the right of the midline and 
1 mm retro-orbitally. The skull was exposed with a cotton-tip applicator and a 
handhold drill was used to drill a hole 1.5 mm anterior to bregma and 0.5 mm right to 
the midline. A 1ul cell suspension of 3x105 cells was injected using a 30-gauge 
needle attached to a Hamilton syringe and a stereotactic fixation device (Stoelting, 
Wood Dale, IL) at a depth of 1.5 mm underneath the skull surface. The hole was 
covered using bonewax (#W810, Ethicon, Somerville, NJ) and the incision was 
sealed using Vetbond (#1469SB, Vetbond, 3M, Saint Paul, MN). 100ul of Carprofen 
was subcutaneously injected following the surgical procedure as pain reliever. Mice 
were monitored and retained in the study until they displayed any physical or 
neurological symptoms due to tumor burden.  
Xenograft implantation 
Five-week-old five-week-old Athymic Nude Foxn1nu mice were inoculated 
subcutaneously with 5 × 106 dissociated neurosphere cells into the flank on each 
side. Each injection contained a total volume of 200 μL cell suspension in 50% 
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MEM/F12 medium mixed with 50% BD Matrigel™ Basement Membrane Matrix 
(#356234, Becton, Dickinson and Company, East Rutherford, NJ). Caliper 
measurements were conducted weekly to determine tumor volumes using the 
formula V = (length/2) × (width2). 
Magnetic resonance imaging (MRI) 
MRI scans were performed on a 9.4T, 16 cm horizontal bore (Agilent Technologies, 
Inc., Santa Clara, CA) Direct Drive system with a mouse surface receive coil (m2m 
Imaging, Corp., Cleveland, OH) actively decoupled to a whole-body volume transmit 
coil (Rapid MR International, LLC., Columbus, OH). 50ul of 0.5M gadolinium-DTPA 
(Magnevist; Bayer Healthcare Pharmaceuticals, Montville, NJ) was injected 
intraperitoneal to each mouse 5 minutes before the mouse was anesthetized with a 
1-2% isoflurane/air mixture. During MRI, a heated air system (Air-Therm Heater, 
World Precision Instruments, Sarasota, FL) was used to maintain animal body 
temperature. T1-weighted images were acquired for each animal with the following 
parameters: repetition time/echo time = 510/15ms, field of view = 20 x 20mm2, matrix 
size = 128 x 128, slice thickness = 0.5mm, 25 slices, and two averages. Mice were 
screened for tumor burden every week starting the six week post intracranial 
implantation. Mice are randomized into different treatment groups when tumor sizes 
reached approximately 20-30 mm3. Weekly MRI was continued during treatment. 
Image reconstruction and analysis 
Image reconstruction was completed by an in-house software. Tumors are manually 
contoured along the enhancing rim on the T1-weighted images, from which tumor 
volume was calculated. 
Stereotactic biopsy 
Coordinates for MRI-guided biopsy were determined by a fiducial markers attached 
to the whole-body volume transmit coil and VnmrJ software (Agilent Technologies, 
Inc., Santa Clara, CA). The mouse was moved to a stereotactic station along with 
the whole-body volume transmit coil. A 1cm incision was made and the skull was 
exposed with cotton-tip applicators. After biopsy location was recovered using the 
fiducial markers, a burr hole was drilled and a 22GA x 3 7/8” needle (#54722, Inrad, 
Kentwood, MI) attached to a vacuum syringe was inserted into the tumor. Biopsy 
tissues were dissociated and cultured in NMGF medium immediately. Holes covered 
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using bonewax and incisions were sealed using Vetbond. 100ul of Carprofen was 
subcutaneously injected following the surgical procedure. 
Treatment 
For mice bearing intracranial tumors, animals were randomized into treatment 
groups once their tumor volume reached 20-30mm3 by MRI evaluation. 
Temozolomide (LKT Laboratories, St Paul, MN) was suspended in Ora‑Plus 
suspending vehicle (#0574-0303-16, Rotterdam, Netherlands) and administered to 
animals (66mg/kg) orally daily for five days per week. Cranial irradiation was carried 
out one hour post temozolomide treatment. Mice were restrained in a home-made 
plastic restraining device. A lead shield was used so that only the head was exposed 
to radiation using a Kimtron INC-320 orthovoltage irradiator (Kimtron Medical, Oxford, 
CT). A total of 20Gy radiation was delivered to each animal at 2 Gy/day for ten days. 
Maintenance temozolomide was delivered orally three times week every other week 
from the third week till animals reach moribund. For mice with subcutaneous flank 
tumors, animals were randomized into study groups when subcutaneous tumors 
reached an approximate volume of 300 mm3. Temozolomide and radiation were 
delivered via similar administration routes and treatment schedules as described 
above.  Radiation was targeted at local tumor sites with a lead shield. LY2109761 
(AbMole, Houston, TX) was reconstituted using Ora‑Plus suspending vehicle and 
delivered to animals twice per day for five days every week for two weeks. For 
animals treated with temozolomide, LY2109761 and radiation, LY2109761 was 
administered one hour before radiation along with TMZ and six hours post radiation 
treatment. 
RNA sequencing and data analysis 
Pre-treatment and post-recurrence tumor biopsies were collected and cultured in 
NMGF medium for 3 passages. Neurosphere cells (1x105) were used for RNA 
extraction. Total RNA was extracted using TRIzol (#10296010, Life Technologies, 
Carlsbad, CA) and ethanol precipitated per manufacturer’s instructions. RNAseq 
library preparation and sequencing were completed by the DNA sequencing core at 
the University of Michigan. Specifically, 30~45 million 50nt-single-end reads were 
obtained from each sample with an estimated 20~30x sequencing depth. 
Sequencing reads were aligned to a human reference genome (hg19) using Tophat 
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2.0 and the transciptome was assembled by cufflinks 2.1.1 [16, 17]. Differential 
expression analysis was performed using the EdgeR 3.0 package in R 3.0.3 [18-21]. 
Genes with FDR < 0.05 were chosen for further pathway enrichment analysis using 
David Bioinformatics Resources program and GENEmania [22-24].  
Western Blot 
Cells were lysed with NP-40 lysis buffer (1% NP40, 150 mmol/L NaCl, and 25 
mmol/L Tris, pH 8.0) supplemented with protease inhibitors (#11697498001, 
Complete Protease Inhibitor Cocktail, Roche, Basel, Switzerland) and phosphatase 
inhibitors (#04906845001, PhosSTOP, Roche, Basel, Switzerland). Concentration of 
protein was determined using DC Protein Assay Kit II (#500-0112, Bio-Rad, Hercules, 
CA). Equal amount of protein was loaded in each lane and resolved by 4% to 12% 
gradient or 10% NuPAGE Bis-Tris gels (#NP0322BOX, #WG1202BOX, Life 
Technologies, Carlsbad, CA). Proteins were transferred to 0.2-μm nitrocellulose 
membrane (#162-0112, Bio-Rad, Hercules, CA Membranes were incubated 
overnight at 4°C with primary antibodies after blocking, followed by incubation with 
appropriate horseradish peroxidase (HRP)–conjugated secondary antibody at room 
temperature for 1 hour. Amersham ECL Prime Western Blotting Detection Reagent 
(#RPN2236, GE Healthcare&Life Sciences, Fairfield, CT) was used to detect the 
activity of peroxidase according to the manufacturer's protocol. Antibodies raised 
against Cdk6, Thy1, Sox2, Gli2 were purchased from Cell Signaling Technology 
(#3136, #9798, #2748, #2585, Beverly, MA). ZEB2 antibody was purchased from 
Santa Cruz (#sc-48789, Dallas, Texas) and VCAN, GAPDH-HRP conjugated 
antibodies were purchased from Abcam (#ab19345, #ab9385 Cambridge, England). 
qRT-PCR 
Total RNA from neurosphere cells was extracted as described in RNA sequencing 
session. 2.5ug RNA was subjected to reverse transcription using SuperScript® III 
First-Strand Synthesis System (#18080-051, Life Technologies, Carlsbad, CA). 
qPCR was performed in triplicates using the SYBR Premix Ex Taq II (Tli RNase H 
Plus)(# RR820L, Clontech, Mountain View, CA) and Mastercycler ep realplex2 
(Eppendorf, Hamburg, Germany). The qPCR program comprised 95°C for 60s and 
40 cycles of 95°C for 5s, 60°C for 30s. Relative mRNA expression was calculated 
62
based on Comparative C Method (ΔΔC Method) embedded in the Eppendorf 
Realplex software. The list of primers is included in the table 3.1.  
3.3 Results 
Recurrence of GBM in the presence of IR/TMZ treatment 
Low-passage neurosphere cells were implanted intracranially into immunodeficient 
mice. MR imaging was performed weekly to monitor tumor growth. Once tumor 
volumes reached 20mm3, animals were randomized into three study groups. In 
addition to a control group, mice were treated with TMZ (5 days/week at 66mg/kg, 
orally) and IR (5 days/week at 2Gy/day) for two weeks (TMZ/IR). In a third group, 
mice received the same treatment, but were given adjuvant TMZ every other week (3 
days/week at 66mg/kg, orally) after completion of TMZ/IR treatment (TMZ/IR+TMZ, 
summarized in Figure 3.1A). TMZ/IR was effective in inducing a substantial 
therapeutic response during the first two weeks of treatment wherein control animals 
exhibited a significant increase in tumor volume. Despite an initial response, all 
animals had recurrence with or without adjuvant TMZ. Compared to the TMZ/IR 
group, adjuvant TMZ resulted in a significantly delayed tumor recurrence (10 weeks 
compared to 6 weeks, Figure 3.1B and C). 
An MRI-guided stereotactic intracranial biopsy procedure was used to obtain pre-
treatment tumor tissue when tumor volumes reached 20mm3 (Figure 3.6). 
Additionally, viable tumor tissue was also obtained from moribund animals that 
exhibited tumor recurrence. In order to expand tumor tissue and to eliminate 
contaminating normal mouse brain tissue, samples were cultured as neurospheres 
for less than three passages and used for subsequent molecular analysis. 
Recurrent tumors are resistant to TMZ/IR treatment 
To confirm the therapeutic resistant phenotype of recurrent tumors, pre-treatment 
and recurrent biopsy tumor cells were implanted into the flanks of immunodeficient 
mice. Animals were treated with two-week concomitant TMZ/IR followed by adjuvant 
TMZ. As shown in Figure 3.2A, tumors derived from pre-treatment biopsy cells 
(named as pre-treatment tumors hereinafter) and tumors derived from recurrent 
tumor cells (named as recurrent tumors hereinafter) grew at a similar rate in the 
absence of treatment. In response to treatment, pre-treatment tumors demonstrated 
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a significant delay in tumor growth while recurrent tumors exhibited relative 
resistance to TMZ/IR treatment wherein pre-treatment tumors exhibited a 50% 
decrease in tumor volume, while recurrent tumors exhibited a 750% increase in 
tumor volume (Figure 3.2A). To confirm these findings in the appropriate tumor 
microenvironment, intracranial tumors were established using pre-treatment biopsy 
cells or recurrent tumor cells. Mice were enrolled into an untreated control group or a 
treatment group (TMZ/IR + TMZ) (Figure 3.2B). In agreement with the results from 
flank tumors, intracranial recurrent tumors were more resistant to the combination 
therapy than pre-treatment tumors, wherein the mean tumor volume was 106.7mm3 
in recurrent tumors compared to 30.1 mm3 in pre-treatment tumors after two-week 
treatment of TMZ/IR. Median survival of mice bearing pre-treatment tumors was 11.9 
weeks in response to TMZ/IR+TMZ treatment (Figure 3.2C). In contrast, mice with 
recurrent tumors had a decreased median survival of 7 weeks in response to 
treatment, further confirming that these samples were inherently resistant to the 
combination therapy. 
RNA sequencing reveals functional gene clusters in recurrent tumors  
In order to delineate the mechanistic basis for the observed resistance to therapy in 
recurrent samples, the gene expression profiles of three independent pre-treatment 
biopsies and four recurrent samples were evaluated using RNA sequencing. 1159 
genes were found to be significantly differentially expressed between the two groups 
(FDR<0.05, Figure 3.3A). Among the 1159 differentially expressed genes, 645 genes 
were upregulated in recurrent tumor samples while 514 genes were downregulated. 
Unsupervised clustering analysis showed that each of the independent replicate pre-
treatment biopsies and recurrence samples had a similar gene expression pattern 
(Figure 3.3A). Moreover, the gene expression profiles of each pre-treatment sample 
closely resembled that of the original patient derived neurospheres (Figure 3.7), 
demonstrating that gene expression profiles did not drift significantly during in-vitro 
expansion or upon intracranial tumor growth.  
We then used David functional annotation analysis to identify common cellular 
events that underlie these changes in gene expression. Twenty functional clusters 
within the upregulated genes and thirteen functional clusters in downregulated genes 
were identified (FDR<0.05). Consolidation of clusters having the same genes under 
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different functional annotations yielded ten upregulated gene clusters and seven 
downregulated gene clusters (Figure 3.3B). Of the seven downregulated clusters, six 
were associated with apoptosis and cell death (Figure 3.3B). Functional clusters 
involved in cell adhesion, neuronal differentiation/development, and cellular 
morphogenesis were dominant in the upregulated genes (Figure 3.3B).  
To evaluate the clinical significance of these differentially expressed genes, a 
metagene score was created based on the average gene expression level of 54 cell 
adhesion genes. We selected GBM patients treated with TMZ and IR from TCGA 
(the Cancer Genome Atlas) database and ranked them based on their metagene 
scores. Overall survival and tumor-progression-free days were evaluated in the 
patients with a high metagene score (upper 1/3 total selected patients) and those 
with a low metagene score (lower 1/3 of total selected patients). As shown in figure 
3.3D, patients with a high cell adhesion metagene score had worse clinical outcome, 
both in terms of survival days and tumor-progression-free days, supporting the 
experimental mouse derived results that an increase in a cell adhesion signature 
correlates with a therapeutic resistant phenotype.  
Mesenchymal and stem cells markers are enriched in TMZ/IR resistant tumors 
Within the cluster of genes involved in cell adhesion, many, including THY1, ZEB2, 
VCAN and CDK6, have been implicated in driving cells into a mesenchymal 
phenotype [14]. There is mounting evidence for the role of signaling pathways that 
impart a mesenchymal phenotype in mediating therapeutic resistance in GBM [25, 
26]. To investigate the significance of these genes in the development of therapeutic 
resistance, we first conducted studies to validate the RNA sequencing findings. RT-
qPCR as well as western blot analysis confirmed an upregulation of a mesenchymal 
signature (ZEB2, VCAN, THY1 and CDK6) in recurrent tumor samples (Figure 3.4A 
and 3.4B).  
The epithelial to mesenchymal transition has been associated with phenotypic 
properties of stem cells [27]; hence we investigated the expression of stem cell 
markers in recurrent tumors. Genes associated with a neuronal stem cell phenotype 
were also upregulated in recurrent tumors, including Sox2 and Gli2. RT-qPCR and 
western blot analysis (Figure 3.4C and 3.4D) confirmed increased expression of 
these two stemness markers. Expression of CD133 has been associated with 
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stemness in glioblastoma; hence we investigated its expression using FACS analysis. 
Two of the four recurrent tumors exhibited an enrichment of CD133-positive 
population compared to pre-treatment samples (Figure 3.4E).  
TGF-β signaling mediates expression of mesenchymal/stem cell genes and 
resistance to TMZ/IR 
TGF-β signaling plays a key role in epithelial to mesenchymal transition (EMT) and in 
maintaining stem-like cell populations [28-31]. Signaling network and protein 
interaction analysis found that 21/63 genes within the cell adhesion cluster were 
associated with the TGF-β signaling pathway (Figure 3.5A). We utilized LY2109761, 
an inhibitor of TGF-β signaling, to investigate the role of TGF-β signaling in 
modulating mesenchymal phenotype and an associated stem cell phenotype in GBM. 
Animals bearing flank pre-treatment tumors and recurrent tumors were randomized 
into four groups:: a untreated group, a TMZ/IR group where mice were treated with 
TMZ (5 days/week at 66mg/kg) and IR (5 days/ week at 2Gy) for two weeks followed 
by TMZ (3 days/week at 66mg/kg) every other week, a LY2109761 group where 
mice received 50mg/kg LY2109761 twice every day (5 days/week for the first two 
weeks followed by 3 days/week every other week), and a TMZ/IR/LY2109761 group 
where the animals were treated with a combination of the three aforementioned 
treatment modules. As shown in Figure 3.5B, western blotting of treated recurrent 
tumor tissues showed that LY2109761 significantly decreased the expression levels 
of ZEB2, VCAN, THY1, CDK6, SOX2 and GLI2, even in the presence of TMZ/IR, 
demonstrating the key role of the TGF-β signaling pathway in regulating 
mesenchymal and stem cells markers. Furthermore, as a single agent, LY2109761 
failed to show a significant benefit in preventing tumor progression in both pre-
treatment and recurrent tumors. Combination of TMZ/IR with LY2109761 did not 
show significantly enhanced efficacy compared to TMZ/IR alone in tumors derived 
from pre-treatment samples. In contrast, recurrent tumors exhibited partially 
enhanced response to TMZ/IR/LY2109761 treatment, compared to either 
LY2109761 or TMZ/IR treatment alone (Figure 3.5C).  
3.4 Discussion 
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Resistance to TMZ/IR is the leading cause of treatment failures in GBM. In this study, 
we investigated the mechanisms of therapeutic resistance in GBM using RNA 
sequencing and biochemical assays in a clinically relevant mouse model. By 
comparing the gene expression patterns in pre-treatment tumor biopsy samples and 
recurrent tumor samples, we identified a mutual network underlying TMZ/IR 
resistance. This network is dominated by an elevated expression of 
mesenchymal/stem cell markers and a decreased expression of genes related to cell 
death. We showed that the TGF-β signaling pathway played a critical role in 
orchestrating the expression of mesenchymal/stem cell markers and inhibition of the 
TGF-β signaling pathway partially reversed TMZ/IR resistance. 
In order to recapitulate the genomic complexity of GBM, we utilized a patient derived 
xenograft model that preserves key genetic alterations in the original tumors [32]. A 
MRI-guided stereotactic biopsy procedure was established to minimize non-therapy-
induced variations in pre-treatment and recurrent samples. We found that all 
samples from the pre-treatment or recurrent biopsy tumors exhibited similar gene 
expression patterns within the same group, which demonstrated the great 
consistency of the mouse model and the biopsy procedure.  
TMZ and IR are the standard of care for GBM patients. Most of the current studies 
focus on understanding the molecular basis of therapeutic resistance in GBM 
utilizing either IR or TMZ. Although, it is important to understand the effect of 
individual treatments [26, 33, 34], these studies do not mimic the emergence of 
resistance in clinical settings; thus we selected a combination approach according to 
the clinical standard. We showed that adjuvant TMZ prolonged the overall survival 
from 7 weeks to 13 weeks, which demonstrated that adjuvant TMZ was effective in 
exerting selective pressure against tumor recurrence. In addition, TMZ alone and 
TMZ/IR induced resistant tumors exhibited distinct gene expression patterns (Figure 
3.7), suggesting that TMZ/IR and TMZ alone resulted in different treatment response. 
These data demonstrated that the expression pattern in recurrent tumor indeed 
reflected effects caused by both TMZ and IR. 
By RNA sequencing, our study revealed multiple gene clusters associated with 
TMZ/IR resistance. Cell death related clusters were dominant in downregulated 
genes, implying that evading cell death is a critical step in developing TMZ/IR 
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resistance. Among the upregulated gene clusters, the prevalent clusters were 
associated with cell adhesion, extracellular matrix organization, and cell 
morphogenesis. Cell adhesion and extracellular structure organization are essential 
for physical connections, communication, and mobility of cells [35]. Mesenchymal 
transition is a process where cells acquire mesenchymal phenotypes, including 
decreased cell adhesion, enhanced migratory capacity, and remodeling of 
extracellular matrix [36]. Besides the functional resemblances between 
mesenchymal transition and the top upregulated gene clusters, we also found 
enrichment for mesenchymal markers in recurrent tumors, suggesting that the 
mesenchymal phenotype might be involved in GBM recurrence. In fact, a few studies 
have suggested that the mesenchymal phenotype is associated with poor outcomes 
and therapeutic resistance to both conventional therapies and targeted therapies in 
glioma [14, 26, 37, 38]. For example, Mao et al. showed that radiation induced 
proneural-to-mesenchymal transition in glioma sphere like cultures and the 
mesenchymal signature was associated with radiation resistance [25]. However, the 
mechanistic relationship between mesenchymal phenotype and therapeutic 
resistance is still unclear. 
Some studies found that mesenchymal signature genes modulate DNA repair 
pathways, which might lead to chemoradioresistance. ZEB1 and ZEB2 are two EMT 
master transcription factors, which are regulated by the TGF-β pathway. ZEB2, 
which was upregulated in TMZ/IR resistant samples, has been shown to affect 
ATM/ATR functions in response to DNA damage [39]. ZEB1 promotes 
radioresistance in breast cancer by regulating stability of CHK1. It also regulates 
TMZ sensitivity via regulation of MGMT in glioblastoma [40, 41]. These data 
suggests that mesenchymal transcription factors contribute to TMZ/IR resistance by 
modulating DNA damage response. 
Mesenchymal transition is associated with generation of cancer stem-like cells. 
Weinberg et al. demonstrated that cancer cells possessed high plasticity and 
epithelial to mesenchymal transition (EMT) generated cancer stem-like cells [27, 42]. 
THY1, a candidate gene identified in our study, is among the top upregulated 
membrane proteins during EMT and cells with high expression of THY1 presented 
stem-like properties [43]. Interestingly, the second top enriched gene cluster in 
recurrent tumors is related to neuron differentiation, suggesting that neuron stem cell 
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genes might be involved in therapeutic resistance. Indeed, we identified neural stem 
cell transcription factors with elevated expression in recurrent tumors, including Sox2. 
Sox2 is one of the four core transcription factors that are capable of reprogramming 
differentiated GBM cells into stem-like tumor-propagating cells (TPCs), which drive 
tumor progression and therapeutic resistance [44]. Meanwhile, our study showed 
that the fraction of cells expressing CD133, a putative cancer stem-like cell marker, 
also increased in recurrent tumor samples. Enrichment for a CD133 positive 
population was shown to promote radioresistance via preferential activation of DNA 
damage response [45]. Taken together, our findings suggest that the population of 
stem-like cells was capable of surviving TMZ/IR treatment, which led to tumor 
recurrence.  
The TGF-β signaling pathway is a master regulator of EMT and cancer stem-like 
cells. It can induce EMT through a number of transcription factors, including Snail, 
Slug, ZEB1, ZEB2, Twist, Goosecoid, and FOXC2 [36]. These transcription factors 
execute EMT reprogramming and grant cells mesenchymal phenotypes. Meanwhile, 
TGF-β signaling plays a critical role in maintaining cancer stem cell population in 
various types of cancer, including breast cancer, leukemia, and glioblastoma [28-30, 
46]. Two groups have independently demonstrated that inhibition of TGF-β pathway 
caused decreased expression of stem cell markers, compromised neurosphere 
initiation capability, as well as delayed tumor growth in mice [29, 30]. Here we found 
that the TGF-β signaling pathway regulated the expression of mesenchymal and 
stem cell markers and modulated sensitivity to TMZ/IR treatment. 
Besides changes at the transcription level, other alterations might also take place at 
the post-transcription level while developing therapeutic resistance. The methylation 
status and expression level of MGMT have been implicated in TMZ resistance in 
multiple studies. Here we found that the MGMT promoter was unmethylated in both 
the original patient derived neurosphere cells and pre-treatment tumor cells. Not 
surprisingly, the MGMT promoter of recurrent tumor cells remained unmethylated in 
recurrent tumor cells (Figure 3.8A). However, MGMT mRNA was moderately 
upregulated while the protein level increased substantially in recurrent tumor cells 
(Figure 3.8B&3.8C). Since MGMT participates in repairing TMZ induced DNA 
alkylation, the elevated level of MGMT protein might contribute to TMZ/IR resistance. 
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It also suggests that besides MGMT promoter methylation, there might be other 
mechanisms of MGMT regulation to be discovered.  
Overall, we identified a network underpinning therapeutic resistance in GBM, which 
is dominated by an increased expression of mesenchymal/ stem cell genes and a 
decreased expression of genes involved in cell death. We also demonstrated that 
TGF-β signaling regulated mesenchymal/stem phenotype and partially restored the 
sensitivity to TMZ/IR treatment in GBM. This study provides a rational for clinical 
investigation of combining TGF-β inhibitors and TMZ/IR in GBM patients. Other 
potential mechanisms of resistance, including post-transcriptional regulation and 
regulation of apoptosis, should be investigated and exploited to fully re-sensitize 
TMZ/IR resistant tumors.  
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Figure 3.1 
Figure 3.1.  Recurrence of GBM in the presence of IR/TMZ treatment. (A) 
Schematic of experiment design. Mice bearing intracranial tumors were randomized 
into three groups once the tumor sizes reached about 20mm3. Besides untreated 
group (control), one group of mice were treated with concomitant TMZ (5 times/week 
at 66mg/kg/day) and IR (5 times/week at 2Gy/day) for two weeks followed by 
adjuvant TMZ every other week (3 times/week at 66mg/kg/day) till animals reached 
moribund (TMZ/IR+TMZ). A third group only received concomitant TMZ and IR for 
the first two weeks (TMZ/IR). MRI was performed weekly to monitor tumor growth. 
Tumor biopsies were obtained pre-treatment and post-recurrence. (B) 
Representative MR images from control, TMZ/IR and TMZ/IR+TMZ groups at week0, 
week2, week7 and week13. Tumors were contoured along the enhancing rim with 
purple lines. (C) Treatment response quantified by percentage change in tumor 
volume in untreated, TMZ/IR and TMZ/IR+TMZ groups. Mean+/- SEM was plotted. 
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Figure 3.2 
 
Figure 3.2. Recurrent tumors are resistant to TMZ/IR treatment. (A) Tumor 
response to TMZ/IR+IR treatment in mice bearing subcutaneous pre-treatment and 
recurrent tumors. Pre-treatment and recurrent tumor cells were implanted into left 
and right flanks of immunodeficient mice, respectively. Animals were randomized 
into untreated group and TMZ/IR+TMZ group where mice were treated with TMZ (5 
days/week at 66mg/kg) and IR (5 days/ week at 2Gy) for two weeks followed by TMZ 
(3 days/week at 66mg/kg) every other week. Color bars indicate treatment modules. 
Tumor volumes were measured by caliper every week. Data represents mean+/-
SEM of percentage change in tumor volume. (B) Tumor response to TMZ/IR+IR 
treatment in mice bearing intracranial pre-treatment and recurrent tumors. Mice were 
randomly grouped into an untreated group and a treated group where they received 
TMZ (5 days/week at 66mg/kg) and IR (5 days/ week at 2Gy) followed by TMZ (3 
times/week at 66mg/kg) every other week. Tumor growth was monitored by weekly 
MR imaging. Data represents mean+/-SEM of tumor volumes after two weeks of 
treatment (lower panel). Representative MR images of corresponding tumors are 
shown in the upper panel. Tumors were contoured along the enhancing rim with 
purple lines. (C) Kaplan-Meier survival curve of mice bearing intracranial pre-
treatment and recurrent tumors with or without TMZ/IR+TMZ treatment. Color bars 
indicate treatment modules. 
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Figure 3.3 
 
Figure 3.3. RNA sequencing reveals functional gene clusters in recurrent 
tumors.  (A) Heatmap of differentially expressed genes in pre-treatment (P1,P2,P3) 
and recurrent tumors (R1,R2,R3,R4). (B) Functional gene clusters of upregulated 
and downregulated genes in recurrent tumors. Bar graph represents % total count, 
which indicates the number of genes in each cluster compared to the total number of 
upregulated or downregulated genes. P-value of each cluster was labeled next to its 
column. (C) Heatmap of upregulated cell adhesion genes in pre-treatment and 
recurrent tumor cells. (D) Upper panel depicts overall survival (Left) and tumor-
progression-free (Right) of GBM patients with high and low expression level of cell 
adhesion genes. Lower panel shows characteristics of patients and median survival 
days/tumor-progression-free days in patient groups with high and low expression 
level of cell adhesion genes. 
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Figure 3.4 
 
Figure 3.4. Mesenchymal and stem cell signature genes are enriched in 
recurrent tumor. (A)&(B) RT-qPCR and western blot of mesenchymal signature 
genes (ZEB2, VCAN, THY1 and CDK6) in pre-treatment and recurrent neurosphere 
cells. (C)&(D) RT-qPCR and western blot of stem cell genes (GLI2 and SOX2) in 
pre-treatment and recurrent neurosphere cells. (E) FACS analysis of CD133 
expression in pre-treatment and recurrent neurosphere cells. 
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Figure 3.5 
 
Figure 3.5. TGF-β signaling mediates expression of mesenchymal/stem cell 
markers and TMZ/IR resistance. (A) Pathway and protein interaction analysis of 
the TGF-β pathway in cell adhesion genes. (B) Western blot of mesenchymal/stem 
cell signature genes in recurrent tumors treated with TMZ/IR (Lane 3-7), a TGF-β 
inhibitor (LY2109761, Lane 8-11) or a combination of TMZ/IR and LY2109761 (Lane 
12-16). Lane 1&2: pre-treatment and recurrent neurosphere cells without treatment. 
Pre-treatment and recurrent tumor cells were implanted into left and right flanks of 
immunedeficient mice, respectively. Animals were randomized into four groups: a 
untreated group, a TMZ/IR group where mice were treated with TMZ (5 days/week at 
66mg/kg) and IR (5 days/ week at 2Gy) for two weeks followed by TMZ (3 days/week 
at 66mg/kg) every other week, a LY2109761 group where mice received 50mg/kg 
LY2109761 twice every day (5 days/week for the first two weeks followed by 3 
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days/week every other week), and a TMZ/IR/LY2109761 group where the animals 
were treated with a combination of the three aforementioned treatment modules. 
Tumor samples were collected at 6 weeks post treatment initiation. (C) Quantification 
of % change in tumor volume of pre-treatment and recurrent tumors in response to 
TMZ/IR, LY2109761 TMZ/IR/LY2109761. Tumor volumes were measured by caliper. 
Each dot denotes one tumor, and the horizontal line shows mean values of %change 
in tumor volume of each group. 
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Figure 3.6 
                      
Figure 3.6 Representative images acquired post MRI-guided stereotactic 
biopsy. The MRI-guided stereotactic biopsy procedure was performed as described 
in section 3.2 when tumor sizes reached 20mm3. T1W weighted Gadolinium-
enhanced image sequences were acquired post biopsy sampling. Red arrows 
indicate the biopsy location. Slice thickness: 0.5mm. 
 
 
Figure 3.7 
                                            
Figure 3.7 Unsupervised clustering analysis of gene expression in pre-
treatment and recurrent tumors. Samples include original neurosphere cells 
derived from the GBM patient, pre-treatment tumor cells (P1, P2, P3), recurrent 
tumor cells treated with TMZ/IR+TMZ (R1, R2, R3, R4), and recurrent tumor cells 
treated with TMZ (recurrent tumor, TMZ treated). 
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Figure 3.8 
 
Figure 3.8 Expression of MGMT protein increases in recurrent tumor cells. (A) 
Methylation specific PCR of pre-treatment and recurrent samples and two 
neurosphere samples with charactreized MGMT status. (B) qRT-PCR of pre-
treatment and recurrent samples. (C) Western blot of pre-treatment and recurrent 
samples.  
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CHAPTER IV 
Conclusion and Future Directions 
4.1 Summary of thesis work 
Therapeutic resistance is a major challenge in current clinical management of 
cancer. This thesis sought to dissect the mechanisms of therapeutic 
resistance by utilizing molecular imaging and integrated genomic analysis in 
clinically relevant mouse models. New therapeutic strategies are proposed to 
overcome therapeutic resistance by targeting key regulatory pathways in 
conjunction with chemotherapy and/or radiotherapy.   
The first part of this thesis focused on understanding mechanisms of 
chemoresistance in ovarian endometrioid adenocarcinoma (OEA). 
Chemotherapy treatment induced activation of AKT signaling, which resulted 
in resistance to apoptosis. Inhibition of the AKT pathway enhanced the 
efficacy of chemotherapy in a genetically engineered mouse model of OEA, 
which warrants further clinical investigation of the combination of AKT 
inhibitors and chemotherapies. 
Glioblastoma (GBM) is highly refractory to chemoradiotherapy while the 
resistance mechanism remains unclear.  A patient derived xenograft mouse 
model was established to recapitulate the individual genomics and tumor 
relapses of GBM. RNA sequencing revealed the gene expression changes 
associated with chemoradioresistance, including upregulation of 
mesenchymal and stem cell genes as well as downregulation of apoptosis 
genes. Additionally, inhibition of the TGF-β signaling pathway, the core 
regulator of mesenchymal phenotype and cancer stem cells, partially reversed 
chemoradioresistance. 
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Overall, this thesis provides new insights of the AKT and TGF-β pathways in 
mediating therapeutic resistance in cancer. New combination therapy with 
AKT or TGF-β inhibitor and conventional chemoradiotherapy might benefit a 
subset of ovarian cancer and glioblastoma patients. While the findings 
presented here are derived from ovarian cancer and GBM, the discoveries 
and research methods can be applied to other types of cancer as well. 
4.2 Signaling pathways and therapeutic resistance 
As discussed in chapter I, targeted therapies have been shown to improve 
patients’ outcomes by regulating essential oncogenic pathways. It also 
provides possibilities to overcome therapeutic resistance by targeting critical 
pathways in the development of resistance. In this thesis, the AKT and TGF-β 
pathways are proved to be the critical players in therapeutic resistance in 
ovarian cancer and GBM, respectively. Targeting either of the pathways 
improves the efficacy of chemotherapy and/or radiotherapy, which warrants 
further clinical investigation of both pathways in cancer patients.  
4.2.1 The AKT pathway in chemoresistance in ovarian cancer 
The second chapter of this thesis revealed the role of the AKT pathway in 
mediating chemoresistance in OEA through regulation of apoptosis. The AKT 
pathway regulates apoptosis via both direct and indirect mechanisms. For 
example, it can inactivate transcription factor FoxO family, thus inhibiting 
several pro-apoptotic factors. It can also directly phosphorylate and inactivate 
pro-apoptotic proteins such as BAD [1]. In the case of ovarian cancer, Abedini 
et al. showed that activation of the AKT pathway inhibited cisplatin-induced, 
p53-dependent FLIP ubiquitination and thus inhibited apoptosis, conferring 
chemoresistance in ovarian tumor cells [2]. The mechanism of AKT in 
modulating apoptosis seems to be context-dependent. Further research is 
required to elucidate the regulation axis from AKT to apoptosis in OEA. 
Cisplatin treatment induced AKT activation, but the mechanism remains 
unclear. A precise balance of kinase and phosphatase regulates the 
phosphorylation status of AKT. DNA-PK and ATM has been shown to regulate 
AKT phosphorylation at Ser473 upon DNA damage [3, 4]. Since cisplatin 
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treatment causes DNA damage, AKT might be phosphorylated by DNA-PK or 
ATM in this scenario. A newly published article identified two additional 
phosphorylation sites (S477 and T479) at the extreme C-terminus of AKT1, 
which promoted phosphorylation of S473 to fully activate AKT. Interestingly, 
cyclin A2, which phosphorylates S477 and T479, is tightly regulated 
throughout the cell cycle. As cisplatin causes DNA damage and induces cell 
cycle arrest, cyclin A2 might accumulate and facilitate AKT phosphorylation 
[5]. Since the function of PTEN is compromised in this particular mouse model, 
it might also contribute to accumulation of phosphorylated AKT. Detailed 
research is needed to test this hypothesis. 
OEA accounts for about 10% of ovarian carcinomas while 70-80% of ovarian 
carcinomas are high-grade serous ovarian cancer (HGS-OvCa). A 
comprehensive genomic analysis of 489 HGS-OvCa patients showed that 45% 
of HGS-OvCa patients harbor alterations in the PI3K/RAS pathway [6, 7], 
which suggests that the AKT pathway might also participate in tumorigenesis 
and chemotherapy response in HGS-OvCa. However, thorough research is 
required before we can generalize this knowledge, since OEA and HGS-OvCa 
have distinct genomic signatures as well. For example, mutations in CTNNB1 
gene, which result in dysregulated Wnt signaling pathway, are observed in 
16%–38% of OEA, but are not common in HGS-OvCa [8]. A genetically 
engineered mouse model of HGS-OvCa was recently established with 
Brca;Tp53;Pten defects that are found in human patients [9].This model could 
potentially be utilized to study chemoresistance in HGS-OvCa in the future. 
Given the importance of the AKT pathway in mediating chemoresistance, over 
50 drug candidates targeting the PI3K/AKT/mTOR pathway are under 
development at various stages. Those candidates include AKT inhibitors, 
PI3K inhibitors, mTOR inhibitors and pan-PI3K&mTOR inhibitors. Both 
monotherapies and combination therapies of chemotherapies/targeted 
therapies are being evaluated in clinical trials [10]. But, several challenges are 
present in preclinical studies as well as early clinical trials, such as activation 
of compensatory MAPK pathway and lack of effective patient stratification 
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strategies [11, 12]. Combination therapies and biomarkers are, at present, 
among the top research priorities to establish successful treatment strategies.  
4.2.2 The TGF-β pathway in chemoradioresistance in GBM 
In the third chapter of this thesis, the TGF-β pathway was shown to mediate 
chemoradioresistance by regulating expression of mesenchymal and stem 
cell genes. Yet the mechanistic relationship between mesenchymal/stem cells 
markers, TGF-β signaling and chemoradioresistance still remains to be fully 
explored.  
Mesenchymal cells generally have enhanced migratory capacity, increased 
ECM elaboration, and elevated resistance to apoptosis [13].  The 
mesenchymal phenotype has been associated with resistance to targeted 
therapies and conventional therapies, although the mechanisms are not fully 
understood. The TGF-β pathway is a master regulator of epithelial to 
mesenchymal transition (EMT), which might promote mesenchymal 
phenotypes during development of therapeutic resistance. TGF-β signaling 
has been shown to regulate stem-like cells in various types of cancer, 
including breast cancer. Mani et al. showed that TGF-β signaling drove the 
generation of stem-like cells through EMT [14]. Later, it was shown that stem-
like cells were enriched after chemotherapy, which was regulated by 
increased autocrine TGF-β signaling [15]. This data suggests that 
chemotherapy might be able to activate TGF-β signaling, which leads to 
mesenchymal transition and generation of stem-like cells. The population with 
mesenchymal and stem-like phenotype propagates resistance to 
chemoradiotherapy. In support of this hypothesis, our data has shown that 
TGF-β signaling regulated mesenchymal/stem cell genes and mediated 
therapeutic resistance in GBM. However, it is still unclear what mechanism 
triggers activation of TGF-β signaling. 
Meanwhile, a growing body of evidence suggests that the TGF-β pathway 
regulates the DNA repair pathways, which might mediate 
chemoradioresistance [16]. ZEB1 and ZEB2 are two EMT master transcription 
factors that are regulated by the TGF-β pathway. ZEB2 has been shown to 
affect ATM/ATR functions upon DNA damage [17] while ZEB1 promotes 
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radioresistance in breast cancer by regulating the stability of CHK1 [18]. 
SMAD proteins, which are the major downstream signal mediators of TGF-β 
signaling pathway, form foci at DNA damage sites after exposure to radiation, 
indicating its direct involvement in DNA damage response [19, 20]. This might 
be mediated by ATM, and possibly by p53 as well [21, 22]. Inhibition of the 
TGF-β pathway resulted in decreased number of γH2AX foci, an indicator of 
DNA double strand break, and increased efficacy of radiation in mice bearing 
GBM [23]. Further research is required to understand whether 
chemoradioresistant cells have altered DNA damage capacity and whether it 
is regulated by the TGF-β pathway in our GBM model. 
Overall, the TGF-β pathway is a promising target against 
chemoradioresistance. Various types of drug candidates against the TGF-β 
pathway are in different phases of clinical trials [24]. In the case of GBM, an 
antisense oligo against TGF-β ligand (rabedersen) showed survival benefit in 
recurrent or refractory high-grade glioma and anaplastic astrocytoma in three 
Phase I/II studies [25]. Even though controversies exist about the benefits of 
rabedersen, inhibition of the TGF-β pathway generally shows positive effect in 
cancer patients [24, 26, 27]. Currently, a small inhibitor against the TGF-β 
pathway from Eli Lilly is being tested in a clinical trial for newly diagnosed 
GBM patients in combination with standard chemoradiotherapy. This should 
shed light on the clinical benefits of TGF-β inhibitors in GBM patients in the 
near future. Additionally, patient stratification based on clinically applicable 
surrogates should also be taken into account to achieve optimal clinical 
outcomes. Drug resistance from single targeted therapy might also be an 
issue, which could be avoided by appropriate combination therapies. 
To summarize, this thesis demonstrates that mechanisms of therapeutic 
resistance can be identified using state-of-the-art imaging and genomic 
technologies and that this information can be used to reverse resistance-
dictating pathways through the appropriate use of targeted agents. The 
overall methodological approach as well as the specific knowledge related to 
the involvement of AKT and TGF-β pathways in tumor treatment resistance 
should be relevant to other types of cancer with similar genetic background as 
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well. 
4.3 Tumor heterogeneity and therapeutic resistance 
Recent studies have revealed extensive phenotypic and genetic heterogeneity 
between and within tumors, which confounds the research of therapeutic 
resistance. Tumors from different patients exhibit vastly different genetic 
alterations, pathological characters, and treatment response, which is defined 
as intertumor heterogeneity.  Subpopulations of tumor cells in the same tumor 
might have distinct genetic and non-genetic profiles. This so-called intratumor 
heterogeneity might drive the evolution of tumors and emergence of 
therapeutic resistance [28]. While heterogeneity has great influence on 
therapeutic response, neither characters of heterogeneity have been fully 
addressed in previous research. This thesis tackled this problem by utilizing 
clinically relevant mouse models and systematic genomic analysis, which are 
discussed in details in the following section. 
4.3.1 Intertumor heterogeneity 
This thesis attempted to delineate the roles of intertumor heterogeneity in 
developing therapeutic resistance. In chapter III, we established a highly 
reproducible pipeline to study mechanisms of therapeutic resistance in GBM. 
Although we only focused on one patient, this system can be easily scaled up 
with other GBM patient samples. GBM is classified into four subtypes based 
on gene expression profiles, including mesenchymal, proneural, classical and 
neural subtypes [29]. Mesenchymal and proneural subtypes are the most 
prevalent subtypes in GBM, each of which accounts for 30~35% of the total 
cases [29, 30]. The proneural subtype often harbors mutations in IDH1 as well 
as concomitant amplification and overexpression of PDGFRA. The 
mesenchymal subtype is featured with NF1 mutations compared to other 
subtypes. In addition, both published data from patient cohorts and our data 
from animal studies showed that mesenchymal and proneural subtypes have 
different response to chemoradiotherapy [29]. Taken together, this data 
strongly suggests that therapeutic response and development of resistance 
might be driven by distinct molecular events in these two subtypes, which will 
be investigated in our lab. 
87
 
 
The neurospheres used in this thesis were derived from a mesenchymal GBM 
case characterized by the TCGA. Gene expression analysis of all pre-
treatment samples showed enrichment in mesenchymal gene signatures as 
defined by Verhaak et al.. Genetic profiling also revealed key genetic 
alterations in the mesenchymal subtype, such as NF1 deletion, p53 mutation, 
and EGFR amplification in all pre-treatment samples. This data shows that all 
the pre-treatment samples inherited and maintained the mesenchymal 
signatures present in the parental tumor.  
We showed that mesenchymal associated genes were upregulated in 
recurrent tumors, which seems to be counterintuitive given that the original 
GBM case belong to the mesenchymal subtype. It might be due to the 
limitation of the computational classification system. Since the subtype 
signatures are defined by a computer algorithm, they might not represent the 
comprehensive gene spectrum of biological processes. Our data showed that 
the recurrent tumors maintained the key mesenchymal signatures in the pre-
treatment tumors while gaining additional alterations in mesenchymal genes.  
A recent study showed that transient radiation caused transition from 
proneural to mesenchymal subtype in a genetically engineered mouse model 
of GBM [31]. Other studies also showed that mesenchymal transition 
mediated radioresistance in proneural cancer stem cells [32, 33]. These 
studies raise an interesting possibility that different GBM subtypes might 
converge to the mesenchymal phenotype upon acquisition of therapeutic 
resistance. However, the caveat of these studies is that the transient radiation 
or in vitro system does not mirror the clinical settings. We will investigate this 
hypothesis with the experimental platform described in Chapter III. 
In the next stage of our study, at least three individuals from mesenchymal 
and proneural subtypes will be used to illustrate the evolution of therapeutic 
resistance in the two major GBM subtypes. 
4.3.2 Intratumor heterogeneity 
Phenotypic and genetic heterogeneity exists among the cancer cells within 
the same tumor, which have been shown to drive therapeutic resistance in 
multiple types of cancer [34]. Glioma stem-like cells have been found resistant 
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to radiotherapy or chemotherapy either due to high DNA repair capacity or 
quiescent status [35, 36]. Single cell sequencing revealed that a 
subpopulation in primary GBM shared similar transcription profiles with cancer 
stem-like cells, which indicated that cancer stem-like cells might preexist in 
GBM prior to the treatment [37].  
In this thesis, we showed that the expression of mesenchymal and stem cell 
genes are upregulated in recurrent tumors, but it remains unclear whether the 
cells expressing mesenchymal/stem cell genes are resistant to 
chemoradiotherapy and whether this population exists prior to treatment 
initiation. In order to address these questions experimentally, we choose 
THY1 (membrane protein) as a surrogate to isolate potential resistant 
population. THY1 is among the highest upregulated membrane proteins 
during EMT and cells with high expression of THY1 presented stem-like 
properties [38]. We plan to first identify and isolate THY1 positive (THY1+) 
and THY1 negative (THY1-) cells in both pre-treatment and recurrent tumor 
cells. Then we will examine the gene expression patterns and therapeutic 
response of THY1+/THY1- cells both in vitro and in vivo, which will be 
compared to pre-treatment and recurrent tumor samples as well. We 
hypothesize that the THY1+ population would show resistance to TMZ/IR and 
express high level of mesenchymal and stem cell markers. This hypothesis 
should potentially enable us to determine the origin of the resistant population 
as well as identify a new biomarker for treatment response to TMZ/IR. 
4.4 Future directions  
Therapeutic resistance is still a pervasive barrier in developing successful 
cancer therapies. This thesis is a pilot to develop a pipeline to optimize 
therapeutic paradigms in cancer. First, tumor heterogeneity was successfully 
recapitulated in both ovarian carcinoma and glioblastoma by leveraging the 
advantages of clinically relevant models. Second, mechanisms of therapeutic 
resistance were identified by both candidate-driven and discovery-driven 
research approaches. Third, treatment response was improved by targeting 
these essential regulatory pathways in therapeutic resistance. This thesis 
successfully proved the feasibility of this pipeline to develop novel therapeutic 
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combinations. The following section will focus on potential improvement in the 
future. 
4.4.1 Maximizing the power of mouse models  
This thesis dissected the mechanisms of therapeutic resistance in one 
individual GBM patient and one subtype of ovarian cancer. Given the 
heterogeneity within each cancer type, it is important to treat each tumor 
individually based on its own genetic profile. GEMMs and PDX used in this 
thesis provide the ideal platforms to mirror individual tumor in laboratories for 
mechanistic research, which bridge the clinical and laboratory demand. 
While GEMMs and PDX are great model systems to recapitulate various 
types of cancer, both of them have some weaknesses. For PDX models, one 
major concern is the lack of a fully functional immune system. As the immune 
system plays an important role in therapeutic response, caution needs to be 
taken when evaluating results from PDX models. However, new methods are 
emerging to compensate this disadvantage in PDX models. For example, 
Wege et al. co-transplanted human hematopoietic stem cells (HSCs) and 
human breast cancer cells into neonatal NOD-scid IL2Rγ(null) mice. They 
observed that a humanized immune system formed in mice while tumor cells 
grew without evidence of rejection [39]. This study brings the hope of 
producing humanized PDX models in the future, which will grant high fidelity 
of recapitulating human cancer in PDX mice. 
GEMMs, which have fully functional immune systems, face their own 
limitations. One drawback is that most of the current GEMMs rely on limited 
oncogenic alterations, which might not be sufficient to recapitulate the 
complexity of cancer genomes. CRISPR/Cas-mediated genome engineering 
provides a straightforward method to generate GEMMs with multiple genetic 
deletions in a timely manner. This can greatly facilitate future cancer modeling 
with GEMMs [40]. 
Besides providing a platform to study mechanisms of therapeutic resistance in 
individual patients, GEMMs and PDX models can also be utilized to evaluate 
the efficacy of personalized therapies. The challenge, however, is the duration 
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of this process. Co-clinical trial is an alternative to speed up the process. In 
2011, a proof-of-principle study was carried out using patient derived 
xenograft models. Tumors from 14 patients with refractory advanced cancers 
were propagated in immunodeficient mice. 232 treatment regimens with 63 
drugs were tested in those PDX mice and effective regimens were identified 
for 12 patients [41]. Another pilot study proved that GEMMs can be used to 
predict results of clinical trials as well as provide guidance for revising 
treatment regimen. In this particular case, the co-clinical trial challenged the 
patient stratification system based on a single genetic biomarker. It 
demonstrated that defects in additional tumor suppressors impaired the 
efficacy of targeted therapy and chemotherapy in GEMMs [42], which might 
explain the inconsistent response among the patients. It also identified new 
predictive genetic markers for resistance in patients for future trial designs. 
Overall, personalized clinical trials in mouse models will greatly improve the 
efficiency of therapeutic optimization and thus benefit cancer patients. 
To summarize, the ideal scenario includes three steps: 1) each individual 
tumor is mirrored in a pre-clinical mouse model; 2) the drivers of therapeutic 
resistance are identified as targets for personalized medicine; 3) treatment 
regimens and schedules are optimized in mice before delivering to patients. 
4.4.2 Cocktail therapy for chronic cancer management 
This thesis showed that targeting master regulatory pathways of therapeutic 
resistance improves the efficacy of chemoradiotherapies. However, multiple 
mechanisms might contribute to chemoradioresistance, as demonstrated in 
the third chapter of this thesis. Meanwhile, failures of single targeted therapy 
in clinical trials prove that monotherapy is not sufficient to rescue 
chemoradioresistant patients. Even when some patients do respond to 
monotherapy, drug resistant clones quickly arise and contribute to tumor 
recurrence [43]. Therefore, it is critical to target multiple pathways of 
resistance simultaneously. This would maximize the cytotoxicity in tumor cells 
while minimizing the likelihood of emergence of new drug resistance. 
In fact, the concept of combination therapy is not new in disease management. 
For example, HIV used to be a lethal disease due to the development of drug 
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resistance. Now the standard HIV treatment usually includes two or more drug 
classes targeting different anti-viral mechanisms, which minimizes the 
chances of selecting resistant clones and prolongs the time to acquire 
resistance mutations against multiple drugs. This combination therapy has 
generated significant clinical impact and turned the fatal disease into a chronic 
manageable condition [44]. 
It might not be that far away to bring this hypothesis to cancer clinical practice. 
First of all, a substantial number of targeted agents against critical therapeutic 
resistance pathways have already been developed and proven to be safe in 
patients. Those targeted therapies cover almost all the known mechanisms of 
therapeutic resistance, including DNA repair pathway, oncogenic pathways, 
apoptotic pathways, and so on. This provides multifarious possible 
combinations for each patient. Meanwhile, increasing number of drug 
candidates against new targets are in active pre-clinical or clinical 
development [45].  
Secondly, it’s becoming affordable and non-invasive to acquire whole 
genomic information from patients with advanced sequencing technology, 
which enables scientists and clinicians to interpret the comprehensive 
genomic alterations. This will optimize combination therapeutics in two ways. 
Firstly, it will allow utilization of one pathway as a biomarker instead of one 
single gene. Previous targeted therapies have usually relied on alterations of 
one single gene, which sometimes failed to stratify responders and non-
responders. Take the PARP inhibitor trials as an example. PARP inhibitors 
target the compensatory pathway of BRCA1/2 in the DNA repair, which is 
predicted to cause cell death in BRCA1/2 deficient cells. However, some 
ovarian patients without BRCA1/2 mutations also showed response to PARP 
inhibitors. Genome sequencing and network analysis shows that about 50% 
patients with high-grade serous ovarian cancer have defects in homologous 
recombination pathways whereas only about 20% of the patients have defects 
in BRCA1/2 mutations, which might explain why patients without BRCA1/2 
also responded to PARP inhibitors. Secondly, genomic profiling will identify all 
potential actionable pathways, which will maximize the efficacy of combined 
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therapy without overlapping or missing any targets. Moreover, liquid biopsies, 
including circulating tumor cells and circulating tumor DNA, have been shown 
to mirror genome alterations associated with therapy resistance in advance 
tumors. This non-invasive approach will generate comprehensive genomic 
evaluations of naïve patients to design initial treatment strategies, which might 
prevent occurrence of resistance. Moreover, it enables repeated and real-time 
analysis of tumor evolution during treatment, which can detect new 
therapeutic resistant clones and aid modification of treatment strategies to 
achieve the best outcome [46, 47].  
It is very promising to use combination therapies to overcome drug resistance. 
However, a few issues still need to be addressed. One major challenge is to 
standardize genome interpretation and make it applicable for clinical practice. 
Although both patient genome information and drug resistance mechanisms 
are now available, it is still overwhelming and onerous to design effective 
combination therapy rationally. One promising solution is to construct 
computation models that integrate patient information, treatment response 
and mechanisms of therapeutic resistance, which can be used to predict the 
optimal treatment regimens for incoming patients. Attempts have been made 
to use mathematical modeling for drug resistance studies [48]. One recent 
study established a model with data from 20 patients treated with BRAF 
inhibitor, which can predict tumor response with genetic information and 
disease stages (metastasis) [49]. Another study modeled the response of 
resistant tumors to doxorubicin with experimental mice data, which can predict 
optimal treatment schedules to prevent tumor progression [50]. These 
pioneering studies demonstrated the power of computation modeling in 
therapeutic optimization, which should improve the efficiency of therapy 
designs in clinical settings. 
Another concern of combination therapy is the cumulative toxicity. Although 
targeted therapies are generally less toxic compared to chemoradiotherapy, 
clinical trials still reveal some side effects in patients. This problem may 
become severe when several drugs are used simultaneously. Therefore, 
special attention is required during new drug development to minimize toxicity. 
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Economic and regulatory issues might also become obstacles in clinics, which 
will not be discussed in detail here. 
4.4.3 Cancer treatment in the future 
Figure 4.1 summarizes an optimized approach for the delivery of cancer 
treatment: in phase I, mechanistic knowledge of therapeutic resistance will be 
collected from a heterogeneous patient population. This can be achieved 
through experimental research as demonstrated in this thesis. In Phase II, 
patient information (including genetic and clinical information), treatment 
response phenotypes, and corresponding drug resistance mechanisms will be 
used to construct a computational model, which can stratify future cancer 
patients and predict the optimal therapies for each individual. 
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Figure 4.1 
      
 
Figure 4.1 Future clinical management of cancer. In phase I, tumors from 
Individual patient will be mirrored in clinical relevant mouse models. Key 
regulatory pathways and optimal treatment regimens against therapeutic 
resistance will be identified through mechanistic studies in mice. In phase II, 
patient information, including genomic and clinical information, profiles of 
therapeutic response and key regulatory pathways will be integrated into 
computational modeling. Incoming patients will be stratified by the computer 
algorithm and receive optimal personalized medicine. 
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